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Abstract 
 
This thesis aims to provide new insights into the evolution of the medical device sector 
(MedTech). After the analysis of the history of the sector, I examine the key points that in the 
past 60 years, have led the industry to grow impressively, and I proceed to an analysis of the 
present situation. The scope of the thesis is to understand if what has stimulated the success of 
the sector at the beginning is still important, and if the introduction of new elements has 
positively changed the evolution of the sector. 
The thesis is composed of three works. The first work (chapter 2) is co-authored by 
Dominique Foray and Michele Pezzoni. I analyze how the network structure of inventors in the 
Swiss regions can influence regional innovation performance within MedTech. I aim to 
contribute to the existing literature related to the debate on the importance of inventors’ co-
location for the creation of innovation. I claim that an increased degree centrality of MedTech 
inventors in the regional technological community is positively associated with the number of 
MedTech patent applications in the focal region. Moreover, the presence of MedTech inventors 
in the main component of the regional technological community is positively associated with the 
number of MedTech patent applications in the region. However, local connections are not 
enough to promote innovation. In fact, the results show that intense cross-regional linkages of 
MedTech inventors increase the number of MedTech patent applications in the region. The 
effect is amplified when this network structure is combined with a high degree of centrality of 
MedTech inventors. Thus, it is not only important that an inventor be well connected within her 
region, but also that she be exposed to external knowledge in order to increase her possibility of 
achieving high performance in MedTech within that region. Finally, I want also to understand 
how MedTech is open to other technological domains. I find that the average degree centrality 
and cross-regional linkages of academic inventors and inventors specialized in technologies 
complementary to MedTech affect regional innovation outcomes. 
The second work (chapter 3) is developed in collaboration with Dominique Foray. I 
aim to study the impact of external technologies on the MedTech sector. I start analyzing the 
literature of knowledge spillovers, and I do a comprehensive review of the extant measures of 
knowledge spillovers. I argue that the classical measures based on patent ‘backward citations’ 
should be carefully interpreted. The reason as to why this type of index needs a prudent 
interpretation is linked to the characteristics of different technologies in terms of the speed at 
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which other sectors are capable of understanding, absorbing and using them. Therefore, I 
propose a new formulation of the classical measure of backward citations. 
The third work (chapter 4) is developed in collaboration with Fabiana Visentin. I aim to 
understand the effects of the MedTech regulation that entered into force in Europe in 1993. I 
argue that the regulation has two effects. The first effect is related to the level of radicalness in 
the innovation. I claim that after the introduction of the regulation, and consequently with the 
tightening of the requirements to fulfill, firms became more careful and less motivated to 
propose radical innovations. At the same time, standardization of the requirements across 
European countries gives to firms the possibility of widening their market.   
Keywords: patents, networks, inventors’ centrality, academic inventors, medical devices, regulation, radical, 
incremental, diffusion, knowledge spillover measures 
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Sommario 
  
Lo scopo di questa tesi è di proporre nuove intuizioni relativamente all’evoluzione del 
settore degli strumenti medicali (MedTech), valutando se ció che ha stimolato il successo del 
settore all’inizio sia importante per lo sviluppo attuale e se l’introduzione di nuovi elementi ne 
abbia cambiato l’evoluzione. 
Dopo aver analizzato la storia del settore, vengono esaminati i punti chiave che negli 
ultimi 60 anni hanno portato il MedTech a cresere in misura esponenziale e infine si conclude 
con l’analisi della situazione attuale.   
La tesi è composta da tre articoli. Il primo è stato sviluppato in collaborazione con D. 
Foray e M. Pezzoni. In questo lavoro analizzo come la stuttura della rete professionale di 
inventori nelle regioni svizzere influenzi la prestazione innovativa regionale nel MedTech. Lo 
scopo è di contribuire al dibattito sull’importanza della prossimità degli inventori per l’ 
innovazione. I risultati mostrano che un aumento della centralità degli inventori MedTech 
all’interno della loro comunità tecnologica è associata positivamente al numero di brevetti di 
dispositivi medicali nella regione di riferimento. Inoltre, anche la presenza di inventori MedTech 
nella componente principale della propria comunità tecnologica potrebbe essere associata 
positivamente con il numero di brevetti MedTech nella regione di riferimento. Ciononostante, le 
connessioni locali da sole non sono sufficenti per promuovere l’innovazione. Infine un’ alta 
connessione tra  gli inventori di tecnologie affini a MedTech influenza positivamente la 
performance innovativa della regione. 
Il secondo articolo è stato scritto in collaborazione con D. Foray. Lo scopo è di studiare 
piú in dettaglio l’impatto delle diverse tecnologie sul settore dei dispositivi medicali. Inizio 
analizzando la letteratura relativa ai flussi di conoscenza e proseguo proponendo una revisione 
delle misure piú frequentemente utilizzate. Voglio dimostrare che le classiche misure basate 
sull’uso delle citazioni dei brevetti dovrebbero essere interpretate con cautela. La ragione di ció è 
legata alla diversa velocità alla quale una nuova tecnologia riesce ad essere capita e impiegata da 
un altro settore. Propongo una nuova formula che utilizza le citazioni di brevetto che sia in grado 
di catturare l’effetto delle diverse caratteristiche delle tecnologie.  
Il terzo lavoro è stato scritto in collaborazione con F. Visentin. Lo scopo è di capire 
entrambi gli effetti della regolamentazione entrata in vigore in Europa nel 1993 sull’innovazione 
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del settore dei dispositivi medicali. Il primo è legato al livello di radicalità di un’innovazione. 
Dopo l’introduzione della regolamentazione e in seguito ad un inasprimento dei requisti da 
soddisfare, le aziende siano diventate piu’ prudenti e meno motivate a proporre innovazioni 
completamente radicali. Il secondo effetto è relativo alla espansione geografica del mercato dei 
dispositivi medicali. Infatti la standardizzazione dei requisiti in tutta Europa ha dato la possibilità 
alle aziende di ampliare il prorio mercato. 
 
Parole chiave: brevetti, rete di inventori, centralità, inventori accademici, dispositivi medicali, 
regolamentazione, radicale, incrementale, misure di flussi di conoscenza 
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Chapter 1: Introduction  
 
1.1 Motivation and thesis roadmap 
The medical device sector in Switzerland has performed an extraordinary 
transformation since its early days in the sixties1. The seeds of transformation were planted by six 
Swiss surgeons located in the region of Basel and Biel, who visualized a revolution in the 
treatment of bone fractures.  Their vision concerned not only the definition of new methods to 
fix broken bones, but also the creation of an organization that would involve companies, medical 
schools and doctors: the Association for the Study of Internal Fixation and Fractures (ASIF, or 
briefly, AO). Historically, the reason as to why these surgeons felt the need to collaborate and 
create something new in the field of orthopedics was related to increasing changes in the culture 
and lives of people in the 1950s. The economic boom made cars affordable to a higher number 
of people. At the same time, there was increasing interest in the practice of sports, such as skiing, 
soccer or motor sports. Cars and new sports led inevitably to an increased rate of unpredictable 
accidents. Social concern related to the exponential increase in accidents led, as a consequence, 
to the origination of a new stream of medicine, such as trauma surgery and sports medicine, as 
well as to the creation of accident insurance.  The fact that insurance was forced to pay for the 
medical care and disabilities generated by accidents pushed insurance companies to establish 
collaborations with surgeons. The efficiency of surgical procedures had a high impact on the 
costs of rehabilitation; thus, surgeons were provided with instruments and, even in a few cases, 
were supported by hospital structures. The increasing need for the development of new 
techniques led to the creation of a spontaneous network of innovative surgeons. In Switzerland, 
regional origins have great significance, as well as personal relations among members of the same 
organization. For this reason, in 1958, the AO was created by a group of friends, Müller, Bandi, 
Schneider, Willenegger, and Allgöwer, with the aim of developing and teaching new techniques 
and practices in Swiss, and later, European medical schools and hospitals. The environment in 
which members of the AO were working was characterized by a strong sense of fraternity, high 
harmony, high importance of face-to-face interactions, high levels of trust, and very low 
                                                          
 
1 The history of the medical device sector has been taken from Schlich (2002). 
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competition. The driving force of the AO was to develop new efficient solutions and to build a 
network of practitioners working in different places with the same standardized methods.   
Subsequent to AO’s creation, surgeons felt the need to set up a commonly financed 
laboratory. Their searches were concentrated in the region of Grison and culminated with the 
decision to establish the AO research laboratory in Davos. The region provided a structure to 
the AO for free because it wanted to incentivize the use of this structure for medical purposes. 
At this point, surgeons needed specialized suppliers in order to produce top-quality standard 
tools and devices. Müller contacted a young engineer, R. Mathys, who owned a small metal 
processing factory near Basel. He was convinced about shifting his production plan in order to 
produce only medical technologies. The collaboration between visionary surgeons and engineers 
was very productive, and after two years of trials, failures and experiments, Mathys succeeded in 
becoming the first company to enter the new fast-growing medical device market. Banks also 
played a key role in the emerging ecosystem: after two years of development without any 
products to sell, Mathys accumulated a debt of CHF 300,000, which worried the local bank 
supporting him. However, surgeons used their prestige and reputation to convince the local bank 
to extend credit to Mathys. Thanks to the extended support of the local bank, Mathys, together 
with the AO, soon achieved incredible success, which involved converting the medical world 
everywhere on the planet to a new technique that they collectively controlled. 
Later, surgeons contacted a second firm to develop the same kinds of tools and 
instruments, led by Straumann, a professor at the University of Stuttgart. He was already known 
for developing sophisticated alloys, and he was a specialist in metallurgy. At the same time, the 
surgeons created their own company based in Davos, called Synthes, which was in charge of 
R&D, training and promotion of the new techniques all over the world. Afterwards, a spin-off of 
Straumann entered the market to develop specific manufacturing processes (Foray, 2014). 
Nowadays, it is common sense to expect that devices used on or in the human body 
have to be tested to assure their safety. In the 1960’s, the risk perceived by a device producer 
when introducing a new product into the market was more related to acceptance by surgeons 
than to the fulfillment of general safety requirements. Orthopedic devices had experienced 
reputational issues concerning a lack of standardized material. Some tools were built by more 
experienced craftsman, which were not touched by corrosion, while other tools had a much 
shorter duration and quality. There was no quality control, and thus, in order to earn more 
money, some craftsmen employed a lower percentage of steel than agreed. For this reason, it was 
not an uncommon practice for surgeons to develop personal instruments by themselves. Albin 
Lambrotte was a surgeon and also an instrument maker. Gerhard Kuntscher, a surgeon, met 
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Ernest Phol, an engineer, to develop instruments. Some surgeons decided to pursue a double 
degree in medicine and engineering in order to have the skills needed to develop tools. But 
without any standards, it is impossible to create a discipline. Thus, the very first clinical trials 
were developed by the AO, which takes documentation of all the trials, with the aim of 
standardizing procedures and making them more replicable in order to avoid the production of 
poor-quality tools.  
After the creation of Synthes, the ethical problem of surgeons who were earning money 
from the commercialization of tools surfaced. Thus, one of the rules for AO members who were 
also stakeholders in Synthes was related to the income generated by the trade of medical 
instruments: it stated that each Swiss franc had to be reinvested in R&D.  
Indeed, the AO developed a very fine-grained policy concerning intellectual property 
rights: patents protecting the inventions of special instruments and implants developed by AO 
surgeons or manufacturers were all transferred to Synthes that granted the right to exclusive 
production and marketing of the AO equipment. Synthes also produced the new activity-specific 
public goods (R&D, training and quality standards). Thanks to the AO and the entrepreneurial 
spirit of the SMEs, the emerging ecosystem was remarkable in building connections to integrate 
the dispersed knowledge and to realize the entrepreneurial discovery process, as well as in 
producing a private institution. Synthes was founded to solve the coordination problems arising 
from early growth of the new activity, support capability formation and reward pioneers in such 
a way that spillovers were maximized.  
Again, and in spite of the complex coordination problems, this was a successful process 
without any policy interventions. It involved the structuring of entrepreneurial knowledge that 
was initially dispersed and fragmented (among surgeons and engineers). It also involved the 
creation of private institutions to solve important coordination problems that arose as the new 
activity started to grow.  
Why did I start with this story? I did so because this is a story about the relevance of: 
networks, knowledge spillovers, and (the absence of) regulation as essential determinants of 
R&D, creativity and innovation in the medical device industry. In my thesis, I will take these 
three topics - networks, spillovers, and regulation - to empirically explore their influence on the 
present dynamics of innovation in the medical device industry. 
The reason I became so passionate about this sector, to the point that I wanted to 
dedicate my efforts to it in my PhD thesis, is that medical devices are not only a group of 
instruments and techniques developed to help people with injuries. Rather, they represent the 
products of a social evolution. The core engine of the AO was the network connecting surgeons, 
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patients and industries. The changes happening in that historical period led to more sophisticated 
surgical procedures to address the increasing probability of accidents: people truly perceived its 
necessity in order to feel safe. At the same time, the industry had developed the technology 
necessary to support surgeons, and these surgeons were ready to open their minds and try 
something new. The same revolution could not have happened 10 years before. All of the small 
pieces of this big system formed the basis for what is the medical device sector now. For 
example, the network of inventors of medical devices is still one of the core forces for the 
growth of the sector. This sector is still looking outside, into other new fields such as ICT, to 
ameliorate the tools. Further, additional changes such as the quality control of their instruments 
have formed the basis of the current regulations.  
In the next paragraph, I review the main strands of literature that have helped me 
develop the three parts of my thesis.  In the last paragraph of this introduction, I summarize the 
findings and the contributions of the thesis. 
In the subsequent chapters, I present three studies that theoretically and empirically 
describe the current evolution of this sector. Each study is thought to bring new insights into the 
story of this sector.  
 
1.2 Background Literature 
1.2.1 Collaboration networks and innovation   
The first study of my dissertation focuses on one of the main aspects of the medical 
device sector: the inventors’ networks. In the first chapter of the introduction, I reported the 
story of AO’s creation to show how, since the very beginning, the driving force of innovation in 
the sector was represented by a network of people. This network was composed of people with 
very different backgrounds, such as engineers, craftsmen and surgeons. What they all had in 
common was geographical proximity, a common culture, and the willingness to change 
something. In my first study, I analyze the importance of the network in recent years. My aim is 
to understand what kinds of collaborations contribute to the evolution of the sector, and if the 
composition and role of the network have changed over time. Specifically, I investigate if the 
network is still composed of people with different skills, and if the geographical connotation of 
these collaborations still persists. 
The impact of professional collaboration networks on regional innovation is a relevant 
topic in the innovation literature. Previous empirical findings have suggested that innovation 
exhibits a pronounced tendency to cluster spatially (Feldman and Kogler, 2010). In the 1990s, 
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several works documented the importance of  geographic proximity in fostering knowledge 
flows among co-located agents (Feldman and Audretsch, 1999; Jaffe at al., 1993). Storper and 
Venables (2004) explain the beneficial effects of geographical proximity in knowledge exchanges 
among individuals with an increased likelihood of face-to-face contact. In order to explain the 
beneficial effects of clustering on innovation, the literature relies on the concept of localized 
knowledge spillovers (Döring and Schnellenbach, 2006; Feldman and Audretsch, 1999; Jaffe et 
al., 1993; Zucker et al., 1998). The existence of localized knowledge spillovers is strictly 
connected with the inventors’ social and professional connections (Breschi and Lissoni, 2001; 
Powell et al., 1996). The concept of localized knowledge spillovers has been revisited by 
supporting the idea that a large part of the knowledge flowing among agents cannot be 
considered as a pure externality. On the contrary, flows are mainly regulated by economic 
transactions, such as work contracts, markets for technologies, and research collaborations 
among individuals, firms and institutions. The diffusion of knowledge through these mechanisms 
feeds the creativity of individuals and enhances innovation opportunities (Burt, 2004; Cowan and 
Jonard, 2004). However, it is difficult to think that knowledge networks, being social and not 
territorial constructs, are enclosed within regional borders (Ter Wal and Boschma, 2009; Asheim 
and Isaksen, 2002).  Transcending cross-regional borders with external linkages brings new ideas, 
new information and fresh knowledge into the region (Breschi and Lenzi, 2012; Bresnahan et al., 
2001; Bathelt et al., 2004; Grabher, 1993; Rosenkop and Nerkar, 2001). The lack of external 
linkages, and the consequent isolation of inventors within a region, might lead to a convergence 
toward homogenous, redundant knowledge circulating within the region and resulting in the 
decline of innovation (Bathelt et al., 2004; Burt, 2004; Neal, 2010;  Uzzi,  1997). External linkages 
are not only intended in geographic terms, but are also related to the technology domain. A 
growing strand of literature currently considers a large part of new knowledge generation as the 
result of recombining existing knowledge from different fields (Antonelli et al., 2010;  Kogut and 
Zander, 1993; Mccann and Ortega-Argilés, 2013; Youtie et al., 2008; Weitzman, 1998). In any 
case, it is difficult for focal firms to absorb and interpret knowledge from distant domains. For 
this reason, firms tend to explore only closely related technological domains and pursue 
incremental innovations (Rosenkopf and Nerkar, 2001). However, firms need to look for new 
knowledge in different technological domains in order to refresh existing information and 
develop new assets (Gavetti and Levinthal, 2000). In co-invention networks, inventors 
specialized in different technological domains are expected to have more chances to exchange 
knowledge when they are intensively connected. From the point-of-view of the analysis of 
regional innovative performance, a higher connectivity of inventors leads to higher chances of 
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contributing to regional knowledge recombination (Feldman and Audretsch, 1999). Moreover, 
the importance of the exchange of knowledge between complementary sectors has been 
emphasized by the concept of related variety. The fact that complementary technologies are 
accessible locally increases the probability of regional growth (Bishop and Gripaios, 2009; 
Boschma and Iammarino, 2009; Boschma et al. 2012; Frenken et al., 2007; Quatraro, 2010).  
The importance of creating an intense regional network of collaborations, together with 
the insertion of cross-regional and cross-domain connections is the focus of my first study. 
 
1.2.2 Technological spillovers and innovation 
The second study of my dissertation goes more into the details in terms of the 
interaction of the medical device sector with other technologies. In the first section of the 
introduction, I argued how important precision mechanics were in building the first orthopedic 
tools. Nowadays, the technologies that help MedTech grow are not the same as in the 1960s. 
MedTech has evolved, as well as other technologies. From the beginning of the 21st century, 
MedTech and Information and Communication Technologies (ICTs) have shown very intense 
interaction in terms of technological knowledge exchange.  
ICTs help MedTech in the creation of tools with completely new features. For instance, 
ICTs allow patients to save measurements, keep track of past values of their medical tests, and 
receive reminders for medications. All of the data collected are visible automatically by the 
physician, who can immediately intervene, if needed (Jog et al., 2015). Measurement devices can 
be implanted into the tissue (Yazdandoost and Kohno, 2007) and can transmit wireless data 
collected. ICTs can also be integrated into medical devices, such as infusion devices. In this case, 
the data of a patient are collected and aggregated in a dataset. The dataset is then put in a cloud 
that connects several hospitals. Taking the information anonymously, the software is able to 
compare the values related to different patients with similar conditions and provide suggestions 
on best practices. These are just some examples of the possible applications of ICTs in 
MedTech, but the advantages that the interaction of ICTs with MedTech has brought over the 
years are countless, particularly related to the level of the quality of health services at low cost. 
In the literature, ICTs are recognized as General Purpose Technologies (GPTs). The 
central feature of a GPT is the horizontal propagation throughout the economy and the 
complementarity between its inventions and the development of related applications by other 
sectors. Most often, GPTs do not offer the complete innovative outcome, but the recombination 
of  GPTs with complementary technology enables the creation of new innovative solutions 
(Bresnahan and Trajtenberg, 1995). The interesting effects of GPTs on the growth of the entire 
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economy have led scholars to look for ways to measure the process of knowledge flows. The 
willingness to capture technological knowledge spillovers dates back to 1979, when Griliches  
proposed one of the first attempts to build technological indicators using the indirect R&D of a 
sector to prove that it affects the cross-sectors’ knowledge exchange.  
The first method that uses patent data was proposed by Scherer (1982). He built a 
matrix that counts the exchanges of technologies between the producer and user sectors. He 
used patents, surveys and R&D data. Later, Putnam and Everson (1994) proposed a similar idea, 
the Yale matrix. A second method is the creation of a citation function. In the literature, there 
are different versions of the citation function. The very first one was proposed by Caballero and 
Jaffe (1993) and was partly redefined by other scholars in subsequent years (Hall et al., 2001; 
Jaffe and Trajtenberg, 1996; Popp, 2002). In general, the probability that a patent cites another 
patent is a function of three variables: the diffusion process, the obsolescence rate, and a 
parameter built on the characteristics of the two patents. The advantage related to this approach 
concerns the elimination of some of the noises affecting the citation probability (i.e., the 
examiner, the cohort effect, the country effect, etc.). Finally, another measure very frequently 
used is an index based on patent backward citations, which is the measure I try to improve with 
my study. A patent is a legal document that offers exclusive rights to the owner and to the 
inventors in exchange for public disclosure of the invention. In order to prove the novelty and 
non-obviousness of an invention, its technological content must be compared with previous 
existing knowledge. The applicant and the examiner list the existing literature (patent and non-
patent literature) in order to have a benchmark to judge the effective novelty of the invention. In 
the literature, this measure is called the ‘index of backward citations’. Many attempts have been 
developed to demonstrate that patent citations are a good measure of knowledge flow.  
Jaffe, Trajtenberg, and Henderson (1993) describe the reasons for why patent citations 
are a good proxy to trace spillovers. Citations can be introduced either by the inventors or by the 
patent examiner. While the citations listed by the inventors should be an actual measure of the 
awareness of the knowledge owned, or at least of part of it, the citations added by the patent 
examiner are references to prior art that could be unknown by the inventors. Consequently, 
citations are a ‘very noisy measure for spillovers’. However, at the same time, they are a 
conservative measure: if some significant results appear, they must be correct because they were 
able to emerge, despite the noise generated by the references added by the patent examiner. In 
the same vein, Hall et al. (2001) and Duguet and MacGarvie (2005) add empirical proof to the 
use of backward citations, undergoing surveys to explain the origins of the citations they insert in 
their patents. In both works, the authors find confirmation concerning the capability of 
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backward citations to reflect the inventors’ knowledge, even if the validity changes with the 
source and the destination of the knowledge transmitted. Breschi and Lissoni (2004) explain that 
even if patent citations are added both by the inventor and the examiner, they are both valid. The 
reason is that inventors can have a strategical reason not to disclose the prior art, while 
examiners fill this gap. Recently, Jaffe and De Rassenfosse (2016) have proposed a 
comprehensive overview of the uses and pitfalls related to the measure of backward citations. 
My work aims to propose a new version of the last measure, the backward citation. This 
analysis is inspired by the fact that different technologies require different time periods to be 
understood, and that this variance should be captured in the measure. 
More specifically, I argue that the faster the adoption of a new technology z, the faster 
this new technology z becomes “common knowledge”, and it is no longer cited.  Consequently, 
it becomes invisible in terms of backward citations. 
 
1.2.3 Regulations and innovation 
The third study of the thesis analyzes the effect of the introduction of a regulation in a 
sector that was auto-regulated until the 1990s. As I mentioned in the first section of the 
introduction, when the revolution of the orthopedics sector started, there were no rules for 
setting a quality threshold for instruments, nor did any rules exist to assure safety for patients. 
Only few attempts had been conducted by the AO to ensure the standardization of materials. 
The situation changed at the beginning of the 1990s in Europe, with the introduction of a 
regulation that mandated the safety requirements to be fulfilled by any medical tool before 
entering into the market. This regulation, the “Council Directive 93/42/EEC on Medical 
devices”, takes the place of all individual regulations existing at the national level (if any) and was 
recognized by all European countries.  The effects of introducing this regulation are still the 
cause of significant debates (Ashford et al., 1985; Blind, 2008; Herzlinger, 2006; Rothwell, 1980; 
Stewart, 1981; Verhoeven et al., 2016). Some scholars see regulations as a barrier to evolution. 
Technological innovation positively contributes to economic growth. It represents the engine of 
the economic development process, proving new solutions and opportunities for industries and 
consumers. More broadly, it improves the social welfare by assuring greater consumer abundance 
and by providing new care for diseases. For these reasons, any limitations can only produce 
negative effects. Other scholars, instead, are more concerned about the side effects of 
technological innovation and argue that regulations are necessary to guarantee controlled 
development, which can also be seen as a stimulus for innovation (Porter and Linde, 1995). 
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Others are more inclined to understand “what tradeoff our society is willing to make” (Eads, 
1980, p. 51) between social and economic benefits and the risk of an unconditional technological 
evolution. In fact, regulation has the difficult task of finding a trade-off between risks and 
benefits, and in doing so, it has to take into account the social and economic implications of its 
decisions. In the specificity of the medical device sector, it is particularly hard to understand the 
policy implications of innovation. In past years, the development and complexity of new devices 
have required a careful assessment of the quality and safeness of tools. This has led to the 
creation of connections among agents: public health, clinical specialties, epidemiology and 
academic disciplines, with the aim of producing evidence that a specific device is safe and 
efficient (Faulkner and Kent, 2001). However, regulations are seen by firms as one of the core 
factors that influence the innovation process. In particular, regulation can influence the degree of 
novelty in innovative outcomes. To measure the degree of novelty, innovation can be grouped 
into two types: incremental or radical.  
An incremental or continuous innovation does not bring a fundamental change to the 
treatment, nor a crucial change to the product. It requires a short development cycle and, due to 
the very low degree of change, its acceptance by the market and by the regulation is almost sure. 
Radical innovations are generally defined as breakthroughs, compared to those inventions that 
do not depart from the traditional path, but simply add a few elements of novelty to the existing 
ones (Anderson and Tushman, 1990; Ashford and Hall, 2011). A radical innovation changes the 
treatment paradigm, with the consequence of providing a completely new product. Since this 
innovation is completely new, the reaction of the market is difficult to forecast, as well as the 
response of the regulatory pathway. Therefore, I argue that after the introduction of the 
regulation, MedTech firms feel more risk adverse and are less likely to put completely radical 
innovations on the market. It is likely that the biggest percentage of R&D expenses are used to 
modify and ameliorate existing tools, while only a smaller amount of resources is devoted to the 
invention of a new tool completely from scratch. This innovative behavior will protect firms 
from the rejection of tools by the regulation and will also promote easier acceptance by the 
market, due to the fact that the new tool is an amelioration of a previous one, already in use. 
Nevertheless, the regulation also sets the standardization of requirements, where 
beforehand there were different rules (or none). This led to the second aspect of the analysis: the 
geographical extension of the inventions. I argue that the normalization of conditions to satisfy 
in order to introduce a tool to the market has led firms to be more open to foreign markets. 
Beforehand a company was focused only on its own country, because it was sure that its 
products could be sold there. Now the regulation “Council Directive 93/42/EEC” is the same 
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for all of Europe; thus, the firm can sell everywhere with the certainty of having fulfilled all of its 
requirements.   
1.3 Thesis Contributions 
The first work is positioned in the debate related to the importance of the co-location 
of innovative agents on the introduction of an innovation. Many scholars have stressed the 
importance of being in the same place in order to innovate. However, the mechanisms through 
which spillovers operate have remained a “black box” for a long time. A growing strand of 
literature has criticized the idea that agents belonging to the same spatial cluster benefit from 
costless knowledge externalities simply because they are there. Precisely, it has been shown that 
geographical proximity is not the only determinant of knowledge flows among agents, and its 
effect is largely reduced when other variables, such as co-invention network characteristics, are 
included in the analysis (Bettencourt et al., 2007; Breschi and Lissoni, 2001; Breschi and Lissoni, 
2009).   
 My work aims to shed light on this argumentation. The results show that being located 
in the same place is not the only factor raising the chances of establishing a direct collaboration 
between MedTech inventors. The results also show that close collaborations are enhanced by the 
high intensity of their external linkages. This sheds new light on the importance of external 
linkages. In fact, the outcomes suggest that the capability of a region to benefit from cross-
regional linkages is influenced by its internal network structure. The implications of this work are 
directed toward policy-makers aiming to enhance the regional innovation in a specific sector.  
These findings support the argument of smart specialization, in that a so-called "pipeline 
strategy", implemented to capture extra-regional knowledge, will not succeed if indigenous 
capabilities have not been formed. In other words, a pipeline strategy cannot be viewed as a 
substitute for internal capability failures (Foray, 2014).  
The second work speaks to the literature on technological knowledge spillovers. The 
importance of knowledge spillovers for economic growth is universally recognized. The way in 
which technological knowledge spillovers can be measured has been a hot topic in the economic 
literature. The aim of this work is to propose a new method that can capture technological 
spillovers, taking into account the different speed of adoption for each technology. The results 
show how the speed of adoption of a technology can influence the measure of knowledge 
spillovers using backward citations. The implications of this work are relevant for the literature 
that aims to grasp technological spillovers between different fields. The results suggest that it is 
important to carefully analyze the dynamic behavior of different technologies in order to capture 
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the existing connections more precisely. The correct evaluation of the intensity of technological 
spillovers between sectors has implications for policy-makers whose intent is to understand the 
potential for modernization that would allow a traditional industry to improve its operational 
efficiency or product quality, as well as to experience a transitional move from traditional 
practices targeting old, declining markets to new technologies for entering new, emerging 
markets. The capability to grasp such a phenomenon in the most precise way enhances the 
possibility of having a policy that better fits the real needs of the society.  
The third work adds new insights to the literature on the effects of social regulation on 
the innovation of the industrial sector. This literature claims that public intervention favors 
innovation activities (Porter and van der Linde, 1995), but extant empirical evidence provides 
contradictory results regarding the positive or negative effects of introducing new rules (Blind, 
2012). One of the most difficult tasks of policy-makers is to propose a regulation that assures 
users’ safety, and at the same time, minimizes the side effects on the economic outcomes of 
firms. Unique to this third study is the fact that, in considering the regulation effects on 
innovation activities, I look at the technical content of each invention. Specifically, I consider the 
technologies embodied in an invention. The results show that, after the regulation change, 
innovators tend to replicate extant technology combinations instead of introducing new ones. 
This result thus indicates that innovators become more risk adverse toward novelty. At the same 
time, a stringent regulation at the European level imposes the standardization of products to all 
European countries. If innovators can rely on uniform rules that their products have to satisfy, 
they are incentivized to extend their target markets. When policy-makers introduce a strict 
regulation, they think about the health and security of the final users. However, they should also 
consider the ‘side-effects’ for the economy. A more stringent regulation might discourage 
inventors from introducing new risky solutions.  
Table 1.1 reports the overview of the thesis. 
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 First study Second study Third study 
Empirical Context Medical device sector in 
Switzerland 
Medical device sector in 
Switzerland 
Medical device sector in 
Europe 
 
Referenced Literature 
Network effects on 
innovation; Knowledge 
spillovers; 
Proximity effects 
GPTs; 
Patent backward 
citations to measure 
technological spillovers  
Effect of the regulation 
on innovation; 
Technology diffusion; 
Incremental vs. radical 
innovation  
Research Question(s) What is the best 
network structure to 
enhance regional 
innovation? 
Are backward citations 
still the best measure to 
track knowledge 
spillovers? 
What are the effects of 
introducing medical 
device regulation in 
Europe? 
 
 
 
My Contributions 
Results confirm the 
importance of the co-
location of inventors 
for regional innovative 
performance. The 
positive effect of 
intense relationships 
within the region is 
enhanced by a few 
relationships outside of 
the region and with 
different sectors.  
Introduction of a new 
measure of backward 
citations that  is able to 
account for the 
differences in the 
adoption speed of 
different technologies 
The results show the 
twofold effect of 
introducing the 
regulation on the 
performance of the 
sector. Innovators 
become less risk 
adverse and produce 
less radical innovations; 
at the same time, they 
have the possibility of 
opening their market 
beyond their national 
borders, thus exploiting 
common standards.  
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Chapter 2: Does the centrality of specialized 
inventors foster regional innovation? The case of the 
Swiss medical device sector 
(with Dominique Foray and Michele Pezzoni) 
2.1   Introduction 
Empirical findings suggest that innovation exhibits a pronounced tendency to cluster 
spatially (Feldman and Kogler, 2010). During the 1990s, several works documented the 
importance of  geographic proximity in fostering knowledge flows among co-located agents 
(Feldman and Audretsch, 1999; Jaffe et al., 1993). From this point of view, knowledge spills over 
among co-located firms or individuals simply because they are there, without being regulated by 
economic transactions or by formal contractual agreements among actors. The concept of 
localized knowledge spillovers, used to define the beneficial effect of co-location, has become 
popular and has served as a starting point, both for policymakers aiming to design regional 
innovation policies and for researchers aiming to combine geography and innovation. 
 Storper and Venables (2004) explain the beneficial effects of geographical proximity in 
knowledge exchanges between individuals with an increased likelihood of face-to-face contacts. 
According to the authors, face-to-face contacts facilitate the transmission of tacit and contextual 
knowledge among agents. Bathelt et al. (2004) use the term “buzz” to describe the beneficial co-
presence of individuals in the same city or region.  
However, the mechanisms through which spillovers operate have remained a “black 
box” for a long time. A growing stream of literature has criticized the idea that agents belonging 
to the same spatial cluster benefit from costless knowledge externalities simply because they are 
there. Precisely, it has been shown that geographical proximity is not the only determinant of 
knowledge flows among agents, and its effect is largely reduced when other variables, such as co-
invention network characteristics, are included in the analysis (Bettencourt et al., 2007; Breschi 
and Lissoni, 2001; Breschi and Lissoni, 2009).   
This paper aims to contribute to the current discussion by assessing how the regional 
level of connection regarding technologically specialized inventors and academic inventors 
impacts regional innovation outcomes. It focuses on the Swiss medical device sector (MedTech). 
The analysis considers both the structure of the network related to the regional community of 
inventors and the cross-regional linkages (Bathelt et al., 2004). The inventors are classified 
according to their technological specialization in the medical device technology sector, in 
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technologies complementary to medical devices, and academic inventors. The analysis considers 
two measures of the inventors’ level of connection: degree centrality and the intensity of cross-
regional collaborations calculated for each class of inventors.  
The results show that the average degree centrality of the regional technological 
community specialized in the medical device sector positively correlates with regional innovation. 
Its effect is amplified when specialized inventors also have intense cross-regional collaborations. 
Moreover, regional innovation is affected by the position in the network of inventors specialized 
in complementary technologies that serve as the building blocks of medical device inventions, 
and by the cross-regional collaborations of the academic inventors. 
These findings are relevant for the creation of regional innovation policies. This study 
shows that the level of connection, within and outside of the region, of different groups of 
inventors has different effects on the production of new knowledge in a specific technology. 
Precisely, this study suggests to policymakers which groups of inventors and which types of 
connections should be incentivized in order to foster regional innovative performance in the 
medical device sector.    
This paper speaks to four streams of literature. The first stream of literature relies on 
the empirical works that have investigated the impact of network structure on regional 
innovation outcomes (Bettencourt et al., 2007; Lobo and Strumsky, 2008). Part of this literature 
has focused on the test of the “small world” hypothesis. The “small world” is a particular 
network structure characterized by an ecosystem of clusters connected by long ties (Newman, 
2000). The results of these analyses are mixed (Breschi and Lenzi, 2012; Fleming et al., 2007).  
A second stream of literature to which this paper speaks focuses on the importance of 
cross-regional collaborations, showing that their presence impacts the innovation activity of the 
local technological community (Bathelt et al., 2004; Owen-Smith and Powell, 2004).  
A third stream of literature relies on the idea that innovation is the result of a 
recombination of existing knowledge in complementary domains (Kogut and Zander, 1993). 
Technological domains that are highly connected with other domains offer greater possibilities 
for innovation than less connected domains (Fleming, 2001; Galunic and Rodan, 1998; Mccann 
and Ortega-Argilés, 2013; Youtie et al., 2008). 
Finally, the paper relies on the stream of literature studying the role of academic 
inventors in the co-invention network  (Anselin et al., 2000; Balconi et al., 2004; Lissoni, 2010). 
The paper is organized as follows. Section 2 describes the theoretical framework and the 
contribution of this work to the existing literature. Section 3 provides details on the Swiss 
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medical device sector. Section 4 presents the methodology and the econometric model. Section 5 
discusses the results. Section 6 concludes. 
2.2 Theoretical framework and contribution 
The spatial clustering of economic activities leads to several benefits such as increased 
trust bewteen actors, reduced costs, and higher efficiency of the labor market (Agrawal et al.,  
2006; Feldman and Kogler, 2010). In order to explain the beneficial effect of clustering on 
innovation, the literature relies on the concept of localized knowledge spillovers (Döring and 
Schnellenbach, 2006; Feldman and Audretsch., 1999; Jaffe et al., 1993; Zucker et al., 1998). The 
existence of localized knowledge spillovers is strictly connected with the inventors’ social and 
professional connections (Breschi and Lissoni, 2001; Powell, 1996). The concept of localized 
knowledge spillovers has been revisited by supporting the idea that a large part of the knowledge 
flowing among agents cannot be considered as a pure externality. On the contrary, flows are 
mainly regulated by economic transactions, such as work contracts, markets for technologies, 
and research collaborations among individuals, firms and institutions. The diffusion of 
knowledge through these mechanisms feeds the creativity of individuals and enhances 
innovation opportunities (Burt, 2004; Cowan and Jonard, 2004).  
 In this framework, the co-invention network is a proxy for inventors’ collaborations 
and possible contractual agreements among actors. The nodes in this network are the inventors 
who appear in the patent application documents, and two inventors are connected if their names 
appear in the same patent application. The idea that the properties of the co-invention network 
affect the diffusion of knowledge among inventors has already been investigated in several works 
(Ahuja, 2000; Boschma and Frenken, 2010;  Breschi and Lissoni, 2009; Gomes-Casseres et al., 
2006; Singh, 2005).  
This paper highlights the characterization of the nodes of the co-invention network. 
Inventors are grouped along two dimensions: their technological specialization (Feldman and 
Audretsch, 1999) and their location, inside or outside of the focal region (Bathelt et al., 2004). 
The analysis starts by assessing the impact of the level of connection involving the inventors 
specialized in MedTech on regional innovation outcomes in the MedTech sector. A higher level 
of connection of the inventors specialized in MedTech is expected to enhance the probability of 
knowledge flows from other inventors, creating benefits for their innovative activity.   
The connectivity of inventors in the regional technological community is measured 
according to two indices. The first index is membership to the largest connected component of 
the co-invention network. As discussed by Owen-Smith and Powell (2004), membership to the 
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largest connected component is a sufficient signal that allows members to benefit from access to 
the information available within the local technological community. This work relies on the same 
idea applied to membership to the largest connected component of the co-invention network of 
inventors specialized in MedTech. 
The second index, degree centrality, measures the intensity of connection in the 
regional technological community (Miguélez and Moreno, 2013; Giuliani, 2005). Degree 
centrality consists of the count of direct connections from the focal inventor to the other 
inventors in the network. Direct connections are the most important channels of knowledge 
flows, considering that  the probability of knowledge flows between two inventors decays 
sharply when their distance in the social network increases (Breschi and Lissoni, 2001; 
Vanhaverbeke et al., 2009).    
The consequent hypothesis is that high levels of connectivity involving MedTech 
inventors might enhance regional inventive outcomes in the MedTech sector. This hypothesis is 
split into two subcomponents, according to the measures of connectivity used. 
HP1a: An increased average degree centrality of MedTech inventors in the regional technological 
community correlates positively to the number of MedTech patent applications in the focal region. 
HP1b: The presence of MedTech inventors in the principal component of the regional technological 
community correlates positively with the number of MedTech patent applications in the region. 
It is difficult to think that knowledge networks, being social and not territorial 
constructs, are enclosed within regional borders (Ter Wal and Boschma, 2009; Asheim and 
Isaksen, 2002).  Going through the cross-regional borders with external linkages brings new 
ideas, new information and fresh knowledge into the region (Breschi and Lenzi, 2012; Bresnahan 
et al., 2001; Bathelt et al., 2004; Grabher, 1993; Rosenkop and Nerkar, 2001). The lack of 
external linkages, and the consequent isolation of inventors within a region, might cause 
convergence toward homogenous redundant knowledge circulating within the region and leading 
to the decline of innovation (Bathelt et al., 2004; Burt, 2004; Neal, 2010; Uzzi, 1997; ). Owen-
Smith and Powell (2004) empirically test the impact of the presence of pipelines in the Boston 
biotechnology community. Ponds et al. (2010) and Maggioni et al. (2007) show the importance 
of cross-regional networks in the process of regional innovation. Miguélez and Moreno (2013) 
find that the more inventors within a region collaborate with inventors outside of the region, the 
greater the return on innovation.  
Bathlet et al. (2004) propose a model of local-buzz and global pipelines, where they 
discuss the importance of external linkages for the local cluster. Following the same reasoning, 
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another hypothesis formulated in this paper is that cross-regional linkages do not suffice in 
introducing new knowledge that is beneficial for MedTech innovation outcomes. Inventors who 
are intensively connected with cross-regional collaborations also have to be central in the local 
community of inventors in order to foster the knowledge production process. They can absorb 
and interpret non-redundant knowledge from outside of the region, but they also benefit from 
intense connections within the regional technological community (Cohen and Levinthal, 1990). 
Inventors who are expected to foster the development of a technology within a region have to 
be both embedded in their local network and connected with long ties outside of the region. 
This idea is at the foundation of the smart specialization approach for regional innovation 
(Foray, 2014; Mccann and Ortega-Argilés, 2013; Miguélez and Moreno, 2013).   
Thus, the second hypothesis follows: 
HP2: Intense cross-regional linkages of MedTech inventors increase the number of MedTech patent 
applications in the region; however, the effect is amplified when it is combined with a high degree of centrality of 
MedTech inventors. 
The third hypothesis formulated in this paper regards the role of academic inventors 
and the role of inventors specialized in technologies that are complementary to MedTech. 
Academics play a fundamental role, both in the production of basic research and in the 
production of applied research outcomes (Agrawal and Henderson, 2002). Empirical works have 
shown that academic inventors are frequently involved in collaboration with industry (Azoulay et 
al., 2009; Calderini et al., 2007). However, there are relevant differences between academic and 
industrial researchers. First, the research interests of academic inventors have a border scope 
when compared to industrial researchers (Fleming et al., 2001). Second, Balconi et al. (2004) 
show that academic inventors are more central and better connected than non-academic 
inventors. In particular, their role is to connect the non-academic communities of inventors that 
otherwise would be disconnected. In this sense, academic inventors act as brokers in the 
knowledge network (Lissoni, 2010). The presence of well-connected academic inventors in the 
regional network is expected to enhance inventive MedTech outcomes, increasing the probability 
that different technological communities are connected by academic inventors. Moreover, 
academic inventors might act as brokers in the geographical dimension, having more chances to 
generate new long-distance connections across regional borders. The nature of their professional 
activity favors the generation of cross-regional collaborations through participation in 
conferences, consulting activity, or collaborations with colleagues located in other universities 
(Lissoni and Sanditov, 2006). Academic inventors are particularly important in explaining 
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innovation outcomes in the medical device sector. This sector is characterised by strong 
interactions among different actors such as academics, surgeons and firms (Mina et al., 2007). 
This analysis includes the measures of academic inventors’ degree centrality and cross-regional 
linkages. 
A growing stream of literature currently considers a large part of new knowledge 
generation as the result of recombining existing knowledge (Antonelli et al., 2010;  Kogut and 
Zander, 1993; Mccann and Ortega-Argilés, 2013; Youtie et al., 2008; Weitzman, 1998). It is 
difficult for focal firms to absorb and interpret knowledge from distant domains. For this reason, 
firms tend to explore only closely related technological domains and pursue incremental 
innovations (Rosenkopf and Nerkar, 2001). However, firms need to look for new knowledge in 
different technological domains in order to refresh existing information and develop new assets 
(Gavetti and Levinthal, 2000). In co-invention networks, inventors specialized in different 
technological domains are expected to have more chances to exchange knowledge when they are 
intensively connected. A higher connectivity of inventors leads to higher chances of contributing 
to regional knowledge recombination (Feldman  and Audretsch, 1999). The importance of the 
exchange of knowledge with complementary sectors is the core aspect of the concept regarding 
related variety (Bishop and Gripaios, 2009; Boschma and Iammarino, 2009; Boschma et al. 2012; 
Frenken et al., 2007; Quatraro, 2010). The fact that complementary technologies are accessible 
locally increases the probability of regional growth. 
The medical device sector involves a range of complementarity competencies and 
technologies (Ramlogan et al., 2007). The interdisciplinary nature of MedTech, as described by 
Rosenberg (1994), suggests that innovation in MedTech is the result of recombining knowledge 
flowing from the following technological domains: measurement instruments, pharmaceuticals, 
chemical engineering, machine tools and special machines. This analysis tests whether the degree 
centrality and cross-regional linkages of the inventors specialized in technologies, which are the 
building blocks of MedTech inventions, play a role in boosting regional innovation outcomes.  
The third hypothesis follows:   
HP3: The average degree centrality and cross-regional linkages of academic inventors and inventors 
specialized in technologies complementary to MedTech affect positively regional innovation outcomes. 
The relevant role played by academic inventors and inventors specialized in MedTech 
complementary technologies might affect HP2. Following the reasoning of HP2, the cross-
regional linkages of academic inventors and inventors specialized in MedTech complementary 
technologies might substitute for the MedTech inventors’ cross-regional linkages. As a result, 
academic inventors and inventors specialized in complementary technologies may be left with 
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the responsibility of connecting the local community of inventors to inventors outside of the 
region. 
2.3 The Swiss medical device sector  
This work focuses on the medical device sector in Switzerland. This sector is an 
exceptional success by any measures. It consist of 1,450 firms involved in the production and 
commercialization of medical devices (Swissmedic, 2014). The market of medical devices 
represents 2.3% of the Swiss GDP, with 14 billion CHF per year, accounting for 5.2% of Swiss 
exports. Six percent of Swiss firms have more than 250 employees, while half of them have 
fewer than 10 employees. The first 10 largest firms employ 14,017 workers. The whole sector 
consists of 52,000 full-time employees. The growth rate of sales ranged between 6% and 10% in 
the period 2011-1014 (Medical Cluster, 2014).  
The literature identifies four main features of MedTech. First, MedTech depends on 
complementary technologies from other sectors (Ramlogan et al., 2007). Switzerland develops 
many types of medical devices such as robotics, ortho-dental, and orthopedics. There are 9 
medical clusters in Switzerland. The Leman Lake cluster has relied on the mechanical precision 
and watch industries since 1700. The Neuchatel cluster benefits from the local competencies in 
the industries of precision mechanics and microelectronics. In the north of Switzerland is the 
cluster of Jura, where there is a business incubator for life science companies. The Basel cluster is 
the biggest European life-science cluster. In Solothurn, orthopedic devices are the core product. 
In Bern, medical device firms have the possibility to collaborate with universities of applied 
science, centers of biomedical engineering, and research centers. The cluster of Aargau is 
particularly attractive for the cheap-skilled labor market, and for this reason, the average 
percentage of people employed in R&D is more than the double the Swiss average. The Zurich 
cluster hosts the Swiss Federal Institute, a university, and a large number of successful spin-offs.  
Finally, Ticino hosts the headquarters of many multinational companies active in the MedTech 
sector. 
Second, innovation in MedTech tends to be incremental due to the intrinsic uncertainty 
of the innovation process (Gelijns et al., 1998). MedTech is a sector regulated by strong 
directives that aim to maximize the safety and welfare of patients by minimizing the risk related 
to the use of new devices. Every new product must fulfill strict requirements, quality assessment, 
and clinical trials to enter the market (Chai, 2000).   
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Third, Rosenberg et al. (1995a, 1995b) show how applied research conducted in 
laboratories within firms is more relevant than basic research conducted in universities. On 
average, Swiss medical device companies spend more than 11% of their revenues on R&D. 
Finally, MedTech innovation depends on the interaction of individuals, firms, and 
institutions. Companies need to collaborate with each other in order to develop new products, as 
shown in the Tuttlingen cluster by Halder (2002). Based on a survey conducted by the Swiss 
Cluster2 in 2013, 70% of manufacturers engage in collaborations to develop new products. This 
evidence is supported by the Swissmedic Report, showing that 73% of collaborations are made 
directly with the buyer and can also involve suppliers, universities or other manufacturers in 
minor percentages (Swissmedic, 2014). In particular, academics and surgeons play a fundamental 
role as developers, since they are aware of the potential demand for new devices and the actual 
needs of the final users (Mina et al., 2007). 
2.4 Data and Variables 
The study sample includes 24 Swiss regions. Each region corresponds to a territorial 
unit identified by a NUTS3 code (Sonn and Storper, 2003). The dataset includes all patent 
applications to the European Patent Office (EPO) from 1985 to 2005, for which at least one of 
the inventors is located in a Swiss region. The MedTech applications are classified according to 
the technological classification adopted at EPO3. The study sample is a balanced panel of 504 
observations, i.e., 24 regions observed for 21 years. A patent is assigned to a region if at least one 
of the inventors listed in the patent application reports an address located in that region. In case 
two inventors of the same patent report two addresses located in different regions, full credit of 
the patent is assigned to both regions. 
The count of patent applications classified as MedTech is a proxy for innovative activity 
of the region in the MedTech sector (Ahuja, 2000). The source of patent data is the CRIOS-
Patstat database, which provides a reclassification of patents, according to the disambiguated 
inventors’ identity (Pezzoni et al., 2014; Tarasconi and Coffano, 2014). It relies on an elaboration 
of the Patstat dataset released by the EPO4. 
                                                          
 
2  The Swiss Cluster is an organization that groups together all agents in the value chain of the network involving 
Swiss medical technology. The aim of the organization is to facilitate the creation of collaborations among its 
members. To find out more details about the Swiss Cluster, see: http://www.medical-cluster.ch/   
3A medical device patent is defined as a patent that has the first four digits of the International Patent Classification 
(IPC) equal to: A61B, A61C, A61F, A61H, A61L, A61M, and A61N. Medical devices related to animals and to 
transport or accommodations are not considered. Moreover, the number of patents in these subcategories is 
negligible. 
4 The version of Patstat used for this work is Patstat October 2013. 
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The 24 regions included in our analysis include 38,041 distinct inventors, of which 
3,196 are specialized in MedTech technology. These inventors filed 54,193 patent applications at 
EPO, 5,739 of which are classified as MedTech patent applications.   
The inventors are classified into three groups, according to their technological 
specialization, and whether they are academics or not: 
? inventors specialized in MedTech technologies (MT)  
? inventors specialized in MedTech complementary technologies (MCT) 
? Academic inventors (ACAD) 
The specialization of each inventor is defined according to the predominance of 
specific technologies in the inventor’s stock of patent applications. Precisely, an inventor is 
defined as specialized in MedTech technologies (MT) in year t if she invented at least one 
MedTech patent during the years from t-1 to t-5. An inventor is defined as specialized in 
MedTech complementary technologies (MCT) if she is not specialized in MedTech, but she 
invented at least one patent in a technological domain complementary to MedTech. The 
definition of complementary technologies is based on an analysis of backward citations of 
MedTech patents. The backward citations of MedTech patents are considered during the time 
span t-1 to t-5. Complementary technologies are all of the IPC classes of the patents cited by at 
least one MedTech patent. The most cited complementary technologies are: measurement, 
instruments, pharmaceuticals, chemical engineering, machine tools and other special machines 
(Schmoch, 2008). Not surprisingly, many of these technologies are both the building blocks of 
MedTech technology and the technologies in which Switzerland is historically specialized. 
Finally, the inventors not included in the two preceding categories are classified as inventors 
specialized in other technologies (Other inv.) not relevant for MedTech inventions. 
An inventor is classified as an academic inventor (ACAD) if she has published one 
scientific article reporting an affiliation with a Swiss university. Academic inventors are identified 
using the approach proposed by Dornbusch et al. (2012). First, all of the publications attributed 
to authors with a Swiss university affiliation during the time span 1985-2005 have been collected 
from the Scopus database (a bibliographic database by Elsevier). The authors are selected based 
on their affiliation with university departments in scientific fields that are relevant for MedTech 
inventions, such as engineering, chemistry, biology, and medicine. Then, the names of the 
inventors are matched with those of the authors of the scientific articles5. Finally, the resulting 
                                                          
 
5 The procedure applied allows to identify academic inventors who report on the patent document an address that is 
not the address of the university where they work, i.e. their personal address or the address 
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matches are filtered out in terms of whether the university of affiliation of the author is in a 
region different from the one reported on the patent application document. The result is a list of 
inventors who also appear as authors in published articles. Academic inventors are a subset of 
nodes in the co-invention network. Table 2.1 reports the average number of inventors in each 
class by year and region. 
 
Variable Obs Mean Std. Dev. Min Max 
(1) n. of inventors specialized in MedTech technologies (MT) 504 29.38 43.69 0 321 
(2) n. of inventors specialized in MedTech complementary 
technologies (MCT) 504 176.79 344.57 0 2415 
(3) n. of inventors in other technologies (Other inv.) 504 181.31 168.83 0 1124 
(1)+(2)+(3) n. of inventors  504 387.48 484.08 0 3254 
n. of academic inventors (ACAD) 504 6.95 18.46 0 151 
Table 2.1: Count of inventors in the four categories. The average is calculated by year-region. The 504 observations are the 
result of observing 24 regions for 21 years each. 
The intensity of connections among inventors is measured by degree centrality 
(Freeman, 1978). Degree centrality is defined in two steps. First, for each focal inventor ???all of 
the pi?inventors to which she is connected with a co-invention relationship are counted. More 
formally, the indicator function a?pk, pi? in Equation 2.1 equals one if pk and pi are connected 
with a co-invention relationship, and zero otherwise. The measure of degree centrality (Ct ?pk?) 
in year t accounts for the co-invention relationships over the five-year window from t-1 to t-5 
and n is the total number of inventors. 
 
Ct ?pk?=? a?pk,pi?ni=1 ? (Equation 2.1) 
Second, the average value of the index Ct ?pk??is calculated for the inventors belonging 
to each of the three classes and for the focal region ( trgC ,, ). The index g in Equation 2.2 
indicates each class of inventors: inventors specialized in MedTech (g=MT), inventors specialized 
in complementary technologies (g=MCT), and academic inventors (g=ACAD). trgn ,,  indicates 
the total number of inventors of class g, in region r, in the time window from t-1 to t-5. 
trg
n
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k
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1
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?
??  (Equation 2.2) 
According to Owen-Smith and Powell (2004), belonging to the principal component in 
the regional network is a signal of membership to the regional technological community. In the 
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analysis, MedTech inventors are considered as members of the regional technological community 
if at least one inventor specialized in MedTech is part of the largest connected component of the 
regional network of inventors.  
MedTech inventors’ cross-region linkages are identified with the count of co-invention 
relationships between inventors located within the focal region and inventors located in other 
Swiss regions. The number of co-invention relationships for each focal inventor ?? is calculated 
as in Equation 2.1. However, different from Equation 2.1, the ???inventors are all located outside 
of the focal region. Finally, the average number of cross-region linkages is calculated for each 
class of inventors (as in Equation 2.2). Average cross-region linkages are defined as trgcrossC ,,, . 
The empirical analysis consists of two regressions with different dependent variables 
explained by the same set of regressors. The first dependent variable is the count of MedTech 
patent applications attributed to the focal region in year t (count MT). The second variable is the 
count of all patent applications attributed to the region in year t, without any distinction based 
on their technological classification (Count ALL). The count of all patent applications is included 
in the analysis for the sake of comparison, in order to show that the results obtained for the 
MedTech sector are not accidental. In each Swiss region, on average, there are 116.5 patent 
applications per year, of which 12.6 are MedTech patent applications. The count of MedTech 
patent applications equals zero in 20% of the observations region-year.  
Figure 2.1 shows the average degree centrality of the inventors specialized in MedTech       
( MTC ), in MedTech complementary technologies (
MCT
C ), and academic inventors ( ACADC ). 
After the 1990s, academic inventors are systematically more central than the other two classes. 
This result confirms the empirical evidence in Balconi et al. (2004).  
 
Figure 2.1: average degree centrality of the inventors 
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Two dummies control for cases when average degree centrality cannot be calculated or 
is equal to zero. When there are no inventors of class g in the region in the time span t-1, t-5 
degree centrality cannot be calculated. The dummy n. g inv.>0 equals one if there is a positive 
number of inventors classified in class g within the region, and zero otherwise.  When there are 
inventors of class g in the region, but none of them have co-invention relationships, the degree 
centrality equals zero. The dummy Degree centrality g >0 equals one when the centrality index for 
class g has a positive value, and zero otherwise. Descriptive statistics are reported in Table 2.2.    
Three variables MTcrossC , , MCTcrossC , , ACADcrossC , represent the average cross-regional 
linkages, respectively, for MedTech inventors, inventors specialized in complementary 
technologies, and academic inventors.  
Six dummy variables control for cases when there are no cross-regional linkages of 
inventors of class g. Descriptive statistics are reported in Table 2.2.    
The variables n. MT inv., n. MCT inv., n. ACAD inv., and n. other inv., respectively represent the 
number of inventors specialized in MedTech, in MedTech complementary technologies, 
academic inventors, and the residual number of inventors specialized in other technologies 
within the region. 
Another control included in the regressions is the market structure, as measured by the 
Herfindahl index (H index). A high value of the index means that a few applicants own the largest 
share of patents in region i. The index is calculated over a five-year window from t-1 to t-5. 
Moreover, a control for technological specialization is included in the regression, namely, the 
Herfindahl index of the technological classification of the patents applied for by inventors in the 
region (H index technology).  Calendar-year dummies fixed effects are included in order to control 
for time-varying influences across regions. Regional fixed effects are included to control for the 
time-invariant characteristics of the region. Finally, basic statistics describing the network 
structure, namely, the share of isolated inventors in the network (n. of isolated/(1+n. of inventors)) 
and the share of inventors belonging to the largest connected component (n. of inv. in pr. 
components/(1+n. of inventors)) are included in the regression.  
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Variable Obs Mean Std. Dev. Min Max 
Inventors specialized in MedTech           
Degree centrality MT 504 0.57 0.57 0 2.67 
Degree centrality MT >0 504 0.68 0.47 0 1 
MT cross-regional linkages 504 0.90 1.02 0 11 
MT cross-regional linkages >0 504 0.88 0.33 0 1 
Degree centrality MT * MT cross-regional linkages 504 0.46 0.62 0 3.96 
At least one MedTech inventor in the principal component 504 0.15 0.35 0 1 
log(n. MT inv.) 504 2.55 1.37 0 5.77 
n. MT inv.>0 504 0.95 0.21 0 1 
Inventors specialized in MedTech complementary technologies           
Degree centrality MCT  504 0.60 0.59 0 3.25 
Degree centrality MCT >0 504 0.65 0.48 0 1 
MCT cross-regional linkages 504 0.60 0.63 0 3 
MCT cross-regional linkages >0 504 0.70 0.46 0 1 
Degree centrality MT * MCT cross-regional linkages 504 0.36 0.52 0 3.67 
log(n. MCT inv.) 504 3.17 2.47 0 7.79 
n. MCT inv.>0 504 0.73 0.45 0 1 
Academic inventors           
Degree centrality ACADEMIC  504 0.37 0.79 0 5.45 
Degree centrality ACADEMIC >0 504 0.31 0.46 0 1 
ACADEMIC cross-regional linkages 504 0.32 0.58 0 3 
ACADEMIC cross-regional linkages >0 504 0.33 0.47 0 1 
Degree centrality MT * ACADEMIC cross-regional linkages 504 0.30 0.69 0 5.65 
log(n. ACAD inv.) 504 0.80 1.29 0 5.02 
n. ACAD inv.>0 504 0.42 0.49 0 1 
Other controls           
log(n. other inv.) 504 4.77 1.09 0 7.02 
n. other inv.>0 504 0.98 0.11 0 1 
n. of isolated/(1+n. of inventors) 504 0.60 0.15 0 0.95 
n. of inv. in pr. components/(1+n. of inventors) 504 0.06 0.06 0 0.37 
H index technology 504 0.00 0.02 0 0.33 
H index 504 0.07 0.08 0 0.51 
Table 2.2: Descriptive statistics of the independent variables considered in the regression exercise. The 504 observations are 
the result of observing 24 regions for 21 years each. 
 
2.5 Results 
Table 2.3 shows the results of the regression exercise. Two Poisson models are 
estimated in order to account for the count nature of the dependent variables and for the non-
negligible presence of zero values.  
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(1)  (2)  
 
count 
MedTec
h 
 Count ALL  
 Coeff. Std.Err Coeff. Std.Err 
VARIABLES   
Inventors specialized in MedTech (t-1, t-5)   
Degree centrality MT 0.34*** (0.090) 0.017 (0.028) 
Degree centrality MT >0 0.049 (0.092) 0.034 (0.026) 
MT cross-regional linkages -0.018 (0.051) -0.045*** (0.017) 
MT cross-regional linkages >0 -0.43*** (0.16) 0.096** (0.045) 
Degree centrality MT * MT cross-regional linkages 0.18*** (0.058) 0.0092 (0.021) 
At least one MedTech inventors in the principal component 0.21*** (0.043) 0.065*** (0.015) 
log(n. MT inv.) 0.092 (0.080) -0.032 (0.023) 
n. MT inv.>0 0.61* (0.34) 0.080 (0.078) 
Inventors specialized in MedTech complementary 
technologies (t-1, t-5)     
Degree centrality MCT 0.14** (0.070) -0.028 (0.020) 
Degree centrality MCT >0 0.32* (0.17) -0.068 (0.047) 
MCT cross-regional linkages -0.13 (0.084) -0.066*** (0.022) 
MCT cross-regional linkages >0 -0.35 (0.22) 0.012 (0.065) 
Degree centrality MT * MCT cross-regional linkages -0.12 (0.081) 0.026 (0.023) 
log(n. MCT inv.) -0.046 (0.037) 0.082*** (0.011) 
n. MCT inv.>0 0.37** (0.18) -0.066 (0.054) 
Academic inventors (t-1, t-5)   
Degree centrality ACADEMIC  0.015 (0.069) 0.023 (0.019) 
Degree centrality ACADEMIC >0 0.0031 (0.14) 0.12*** (0.032) 
ACADEMIC cross-regional linkages 0.22*** (0.076) 0.039* (0.021) 
ACADEMIC cross-regional linkages >0 -0.098 (0.15) -0.23*** (0.034) 
Degree centrality MT * ACADEMIC cross-regional linkages -0.26*** (0.066) -0.0099 (0.021) 
log(n. ACAD inv.) -0.098** (0.044) 0.067*** (0.013) 
n. ACAD inv.>0 -0.025 (0.084) 0.023 (0.026) 
Other controls (t-1, t-5)   
log(n. other inv.) -0.019 (0.042) 0.12*** (0.015) 
n. other inv.>0 -1.42* (0.73) -0.077 (0.22) 
n. of isolated/(1+n. of nodes) 0.61 (0.41) -0.093 (0.13) 
n. of inv. in pr. components/(1+n. of nodes) -0.44 (0.53) 0.71*** (0.13) 
H index technology -0.69 (5.37) -2.25 (1.70) 
H index 0.20 (0.46) -0.23** (0.10) 
      
Observations 504  504  
Number of id region 24  24  
Table 2.3: Regression table. Poisson estimations including fixed effects for each region. The 504 observations are the result of 
observing 24 regions for 21 years each. 
 
The average degree centrality of inventors specialized in MedTech (Degree centrality MT) 
impacts positively on the number of MedTech patent applications: one more co-invention 
relationship for the average MedTech inventor increases the number of MedTech patents by 
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34%6 (column 1). Thus, the empirical evidence confirms hypothesis HP1a. Column 2 shows that 
the centrality of inventors specialized in MedTech does not affect the number of patent 
applications in the focal region (count ALL). 
Concerning hypothesis HP1b, the regression in column 1 shows that when at least one 
MedTech inventor belongs to the principal component (at least one MedTech inventor in the principal 
component), the number of MedTech patents in the region augments by 21%. Therefore, 
membership to the largest component of the co-invention network of inventors specialized in 
MedTech stimulates MedTech patent applications. The regression in column 2 shows a similar 
positive and significant effect, although the coefficient is smaller (+6.5%). 
In order to test the second hypothesis (HP2), the analysis focuses on the sign and 
significance of the interaction between the degree centrality of MedTech inventors and the 
intensity of their cross-regional linkages (Degree centrality MT * MT cross-regional linkages). However, 
other actors, such as academics or inventors specialized in technologies complementary to 
MedTech, might act as cross-regional brokers. Then, two additional interactions are included in 
the regression, Degree centrality MT * MCT cross-regional linkages and Degree centrality MT * ACAD 
cross-regional linkages. The regression shows that the coefficient of the interaction term Degree 
centrality MT * MT cross-regional linkages is positive and significant, meaning that the impact of the 
centrality of MedTech inventors is amplified when the MedTech inventors have intense cross-
regional linkages. Concerning the count of all patent applications in the region (Column 2), the 
presence of cross-regional linkages of inventors specialized in MedTech has a negative effect (-
4.5%), and the interaction has no effect. 
Finally, the third hypothesis (HP3) is confirmed. The centrality degree of inventors 
specialized in complementary technologies is positively and significantly correlated with the 
number of MedTech patent applications in the region. This result can be interpreted as the 
beneficial effect of the variety of MedTech complementary sectors in the Swiss regions.  
Moreover, cross-regional linkages of inventors specialized in complementary technologies have 
no impact on MedTech patent applications. The number of all patent applications in the region 
(Column 2) is not affected by the degree centrality of inventors specialized in complementary 
MedTech technologies or by their cross-regional linkages. However, the presence of inventors 
specialized in complementary MedTech technologies has a positive impact on the number of 
MedTech patent applications (n. MCT inv.>0). 
                                                          
 
6 The coefficients of the Poisson estimations are interpreted as suggested by Wooldridge (2015). 
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 Academic inventors’ cross-regional linkages foster MedTech innovation (ACADEMIC 
cross-regional linkages); however, its interaction with the centrality of MedTech inventors shows a 
negative sign (Degree centrality MT * ACADEMIC cross-regional linkages). Precisely, the negative sign 
of the interaction means that when MedTech inventors are central in the network, the role of 
geographical brokerage played by academics is less beneficial for MedTech innovation. When 
focusing on column 2, the academic inventors’ position in the network has some impact, 
especially their representativeness in the local community of inventors (n. ACAD inv.) and their 
connection to other inventors within the region (Degree centrality ACADEMIC >0). 
Concerning the control variables, the technological specialization of the region (H index 
technology) has no impact on the number of patent applications (count ALL) or on the number 
of MedTech patent applications (count MedTech). The concentration of the sector has a negative 
impact only on the number of patent applications (count ALL). 
The number of inventors not specialized in MedTech or in MedTech complementary 
technologies have a positive impact on the number of patent applications (count ALL), but not 
on the number of MedTech patent applications (count MedTech). Similarly, the size of the principal 
component has a positive impact on the number of patent applications (count ALL), but not on 
the number of MedTech patent applications (count MedTech).  
2.6 Conclusions 
This paper aims to contribute to the still mixed literature on the impact of structural 
properties regarding the network of collaborations on regional innovation performance.  
This paper contributes to the previous literature by assessing the impact of structural 
properties involving the regional network of inventors on regional innovation in a specific 
sector: Swiss medical devices. The inventors are grouped according to their technological 
specialization, and whether or not they are academics. Following the methodologies used in prior 
studies, two types of relationships are considered: co-invention relationships within the local 
community of inventors, and cross-regional co-invention relationships.  
The regression results show that the average degree centrality of inventors specialized in 
MedTech positively impacts regional innovative outcomes in the MedTech sector. Moreover, the 
degree centrality effect is enhanced by a high intensity of their cross-regional linkages. The 
interpretation is that cross-regional linkages are effective in bringing new knowledge to the 
region when MedTech inventors are able to benefit from strong connections with the local 
technological community. This sheds new light on the importance of external linkages. The 
results suggest that the capability of a region to benefit from cross-regional linkages is influenced 
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by its internal network structure. Moreover, the central position in the network of inventors 
specialized in technologies complementary to MedTech impacts positively on MedTech 
innovation, supporting the idea that interactions with complementary technologies are necessary 
in order to enhance innovation. Academic inventors act mainly as bridges outside of the region, 
favoring innovation creation. However, when MedTech inventors are central, the role of 
academic inventors as bridges outside of the region is less beneficial for regional MedTech 
innovation.  
Moreover, this analysis shows that the determinants of the innovation outcomes of the 
region for the MedTech sector are different from the determinants of the total innovative 
outcome of the region, showing that the results concerning MedTech are not a pure artifact of 
the analysis.  
The implications of this work are directed toward policymakers aiming to enhance 
regional innovation in a specific sector.  This paper identifies which inventors’ connections, local 
or cross-regional linkages, and which actors in the network are relevant in fostering regional 
innovation outcomes in the MedTech sector. These findings support the argument of smart 
specialization, in that a so-called "pipeline strategy", implemented to capture extra-regional 
knowledge, will not succeed if indigenous capabilities have not been formed. In other words, a 
pipeline strategy cannot be viewed as a substitute for internal capability failures (Foray, 2014).  
This work contains three main limitations. The first limitation is related to the 
definition of MedTech patent applications. According to Directive 93/42/EEC, the MedTech 
sector includes several heterogeneous subgroups. However, in this work, MedTech has been 
considered as a homogenous sector, neglecting differences between subgroups. A second 
limitation regards the scope of the analysis, which is focused on Switzerland. An extension to 
other European countries, applying the same empirical framework, could generalize the results 
obtained. Finally, the last limitation regards the use of patent data. These data cannot cover the 
entire possible range of inventors’ social and professional relationships or all of the innovative 
outcomes of the region. Nevertheless, patents are considered as a good proxy in those sectors, 
where intellectual property provides fairly strong protection for inventions, such as in the 
MedTech sector (Ahuja, 2000). Moreover, longitudinal network data are necessary to assess 
social network impact on innovation. The need for longitudinal data excludes the possible use of 
primary data (such as surveys or questionnaires provided to the inventors), due to the 
impossibility of asking respondents about their social connections in the remote past (Ter Wal 
and Boschma, 2009). 
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Chapter 3: How traditional medical technologies 
integrate ICT: A new methodological approach 
(with Dominique Foray) 
3.1 Introduction 
One of the main questions for policymakers interested in the future of a traditional 
industry regards its potential for modernization. This potentiality would allow the industry to 
improve its operational efficiency or product quality, as well as to experience a transition from 
traditional practices targeting old declining markets to new technologies for entering new 
emerging markets7. 
The broad literature on the historical economics of technologies (David, 1990; David 
and Wright, 1999; Rosenberg and Trajtenberg, 2001) suggests that such a transformation 
potential is fundamentally determined by the capacity of traditional industries to recombine the 
existing knowledge base with new applications of a general purpose technology (such as steam 
power in the XVIII° century, electricity in the XIX° century, or information and communication 
technologies – ICTs -  at the end of the XX° and the beginning of the XXI° centuries). 
It is therefore important to develop adequate methodologies in order to capture such a 
dynamic of knowledge recombination or co-invention between the existing industrial 
technologies in a given sector and new ICT applications. Measuring this knowledge recombination 
should provide new insights into the dynamics of industrial change that an industry has 
experienced in the recent past and should help to predict its incipient future.  
The usual empirical measure of knowledge recombination involves the use of patent 
backward citations8. However, such a measure has some drawbacks. When a new technology - 
say “easyT” - is “easy” to adopt and to be recombined with the existing knowledge base of 
industry I, there is a tendency from both inventors and patent examiners to bypass the backward 
citations to “easyT”; as a result, the dynamics of integrating “easyT” into the existing knowledge 
base of I becomes non-observable. We will show a concrete example of this problem. Our 
hypothesis is therefore that as a new technology is adopted quickly, it disappears as quickly from 
                                                          
 
7 Modernisation is manifest when the development of specific applications of a general purpose technology 
produces a significant impact on the efficiency and quality of an existing (often traditional) sector. Cases in point are 
the development of nanotechnology applications to improve the operational efficiency of the pulp & paper industry, 
or the integration of new information technologies into the footwear industry (Foray, 2014). 
8 See (Jaffe and de Rassenfosse, 2016) for an overview of patent citation data in social science research. 
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the citations’ corpus. The point is that fast adoption makes the new technology quickly become 
“common knowledge”9 for the inventors of industry I, and such “common knowledge” is not 
referred to as backward citations in the new patents of the industry. In such a case, it will be 
necessary to go to the second-stage citation - that is to say, to go deeper into the history of the 
integration of “easyT” - to be able to observe the presence of the new technology in the 
innovation dynamics in industry I.  
In the next section, we recall the main characteristics of a general purpose technology, 
which makes it a key source or opportunity for generating innovation in any traditional sector, 
and in particular, in the sector of medical technologies.   Section 3 discusses the data. Section 4 
discusses the measure of “generality” as a proxy for the diffusion and adoption of general 
purpose technology. Section 5 presents our first round of results, based on the usual backward 
citation methodologies. The results are very much counter-intuitive with ICTs, which are almost 
absent in the medical device innovation picture. Section 6 develops a qualitative case to 
determine what the causes of this observation problem are, and discusses the “easy technology” 
hypothesis. Section 7 presents the current literature on new methods to calculate knowledge 
spillovers. Section 8 explains the different characteristics of technologies in terms of the speed of 
diffusion. Section 9 suggests a new method based on second-stage backward citations – in 
situations where the recombinant process involves an “easy technology.” Section 10 concludes. 
3.2 General Purpose Technologies and medical device innovations 
A central feature of a general purpose technology (GPT) is horizontal propagation 
throughout the economy and the complementary nature between the invention of the GPT and 
the development of applications related to specific sectors. Most often, GPTs do not offer the 
complete innovative outcome, but the recombination of  GPTs with complementary technology 
enables the creation of new innovative solutions (Bresnahan and Trajtenberg, 1995).  
Expressed in the economist’s jargon, the invention of a GPT extends the frontier of 
invention possibilities for the whole economy, while application development changes the 
production function of one particular sector. The basic GPT inventions generate new 
opportunities to develop applications, in particular, “user” sectors. Reciprocally, application co-
invention increases the size of the general technology market and improves the economic return 
on invention activities related to it. The economic structure outlined by the presence of GPTs 
                                                          
 
9 In this paper we use the term “common knowledge” always in brackets in order to avoid a misleading 
interpretation. In fact, a patent could not cite prior inventions but it does not mean that this invention in free and 
public.  
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and user sectors thus creates a round of positive externalities in the economic system. There are 
therefore dynamic feedback loops in accordance with which inventions give rise to the co-
invention of applications, which in turn, increase the return on subsequent inventions. When 
things evolve favorably, a long-term dynamic develops, consisting of large-scale investments in 
R&D, whose social and private marginal rates of return attain high levels.  
To be identified as GPT, a technology must, therefore, possess three characteristics: 
pervasiveness, an innovation-spawning effect and a scope for improvement (Helpman and 
Trajtenberg, 1994). The attribute of pervasiveness implies that GPTs have broad applicability, 
horizontal propagation, and therefore, economic-wide impact. The innovation-spawning effect 
captures the impact of the evolution and innovation of users’ sectors on the growth of the 
“source” GPT. The mutual growth of the GPT, together with the users’ sectors, creates some 
complementarities, which could increase R&D for both, which is the scope for improvement. 
It is acknowledged that ICTs are currently a central GPT and represent the source of a 
great number of innovations in numerous user sectors (Bresnahan and Trajtenberg, 1995). Shin 
and Park (2007) conducted a network analysis on the interaction of ICT as GPTs and user 
sectors; they confirm a strong connection between ICT and other sectors, for example; the 
medical device sector.  
Medical device innovations are characterized by interesting features, which make them a 
good case for studying and measuring the process of knowledge recombination and 
cumulativeness. As Gelijns and Rosenberg (1994) have observed, medical device innovations 
strongly rely on the transfer of knowledge and innovation already generated outside of the 
medical sector, and very often, generated in the industrial world. Thus, medical device 
innovations are not only “inherently interdisciplinary but also outward-looking by nature.” This 
first feature points the centrality of transfer in the medicine of advances regarding electronics, 
optics, computers or material sciences. ICTs are, thus, an obvious source of innovation in 
medical technologies: the development of ICTs provides opportunities to increase productivity 
and improve the quality of a broad range of medical devices10. This happens through the so-
called process of the co-invention of applications, which is the process by which new ICTs 
diffuse across a wide range of sectors, and specific applications are generated.  
                                                          
 
10 A few examples among many of the powerful combinations between ICT and MedTech include devices such as 
body scanners, magnetic resonance imaging and tele-surgery. Moreover, ICT helps the healthcare system in 
providing better quality of service at a lower cost, creating remote access to health services, allowing staff to save 
personal measurements on hospital platforms, and transforming devices for senior patients in user-friendly tools. 
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In the following sessions, we test empirically the interaction of ICTs with MedTech in 
the context of the Swiss medical device industry11. First, we apply the measures usually 
implemented to analyze a GPT and its horizontal propagation and innovativeness. Then, because 
of a few methodological problems that limit the standard method in tracking the dynamics of 
ICT integration in a user sector, we propose developing a new methodology that attempts to 
solve the problems identified. 
3.3 The data  
Medical devices comprise a complex sector, ranging from hospital beds to surgeon 
robots, along with prostheses and tubes for endoscopy. All of these inventions are built on 
different technologies. Given such huge heterogeneity, we decided to focus our work on a 
subgroup of medical devices: orthopedic medical devices. We have two reasons for this choice. 
First, the Swiss industry has a strong record in innovations within this domain of specialization. 
The traditional industrial strengths of Switzerland - precision mechanics and watches – provide 
strong inputs and an optimal environment for medical device firms to generate innovations in 
orthopedic instruments. Second, there is also good reason to expect that the last generation of 
innovation within this domain has been strongly based on the development of specific ICT 
applications, as proved by the numerous recent works on the interaction between these two 
sectors ( Jog et al., 2015; Maulin P., and Wang J. 2010; Winters, J. M., and Wang, Y. 2003 ; 
Yazdandoost and Kohno, 2007) 
We use patent data extracted from July 2015 PATSTAT12 version.  
We retrieve all of the patent applications belonging to Swiss applicants and Swiss 
inventors, applied under the Patent Cooperation Treaty (PCT), the Swiss national patent office, 
the European Patent Office, or at the US Patent office. The identification of the “orthopedics” 
International Patent Classifications (IPCs) was conducted, searching for keywords suggested by 
                                                          
 
11 Studying the dynamics of medical device innovation in Switzerland is motivated by the fact that the Swiss medical 
technology industry is a tremendous success, as documented in many books. By any measure (number of firms, 
employment, added value, number of global innovators, export performance), this industry is in a very high position 
in Switzerland and presents itself as a strong knowledge-driven industry, involving several global leaders. It is also a 
very innovative activity, characterized by a high density of inventors and innovators, as well as a high degree of 
innovativeness of the main customers, which are medical schools and hospitals. See, for instance, “Der diskrete 
Marsch der Schweizer Medizintechnik an die Weltspitze,” in R.Breiding and G.Schwarz, Wirtschaftswunder Schweiz, 
Verlag NZZ, 2011. 
12 PATSTAT is the patent database provided by the European patent office. It contains information about patent 
applications in any national, European, and non-European patent office. 
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one of the experts13 interviewed, inside the definition of each International patent classification 
code14. We identify 58 full-digit IPC codes. This leads to a sample of 9,300 patents from 1980 
until 2013. In all of the results, we have converted the IPC to the TECHNICAL FIELD in order 
to make them more readable. 
In terms of the definition of ICT, we base our decision on the sector description 
provided by Schmoch (2008) and the definition of ICT provided by Hall et al. (2001). Our 
definition of ICT includes four technology fields: Telecommunications, Digital communication, 
Basic communication processes, and Computer technology. 
3.4 Measures of GPT propagation with the “Generality” index 
A frequent indicator used by scholars to observe and measure the horizontal 
propagation of a GPT toward user sectors is the index of generality15. This index is based on an 
analysis of the list of references included in the patent legal document, the backward citations.  
Generality=Gi=1-? sij2nij       (Equation 3.1) 
where i represents the focal patent, while sij  represents “the percentage of citations 
received by patent i that belong to patent class j, out of ni  patent classes.” 
Thus, the expectation is that a GPT will receive a high number of citations from the 
users’ sectors (i.e., pervasiveness, propagation).  Given its other feature of “scope for 
improvement,” the expectation is also that many citations will come from the same GPT.  
Generality is the most frequent measure used to identify GPTs (Callaert et al., 2011; 
Hall and Trajtenberg, 2004; Moser and Tom, 2004; Youtie et al., 2008). However, other works 
(Helpman, 1998; Shin and Park, 2007) propose a different approach, based on network analysis 
to conduct empirical tests on GPTs. However, we do not replicate this procedure. Despite the 
fact that the discussion on the best measures for GPTs is very important when dealing with 
technologies not affected by “easy T”, it is beyond the aim of this paper. 
We calculate the “Generality” index for ICT related to the “Instrument” (Figure 3.1) in 
order to observe and document that ICT plays a central role in medical device innovations16. The 
results in Figure 3.1 show a very high value of the index. This means that ICT patents are cited 
                                                          
 
13 We interviewed three engineers working in three different medical device companies in order to have a more 
realistic and precise overview of the sector. 
14 For more details on the IPC and Technological fields, see Appendix 3.1 
15 For more details on the measure used to capture technological knowledge spillovers, see Appendix 3.2. 
16 See Appendix 3.1 for the definition of the “sector instrument” (WIPO classification). 
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by a broad range of different sectors. Nevertheless, the absolute number of citations from 
different technologies to ICT is actually low, comparing citations to patents of the same 
technological class.  
 
Figure 3.1: Generality index of ICT on the Instrument sector 
 
The Generality index only tells that ICT is cited in many sectors, and as such, meets the 
criteria of horizontal propagation. Moreover, we still do not know whether ICT is an important 
GPT for the MedTech industry. To explore this point further, we need to check the backward 
citations of the MedTech sector to ICT. 
3.5 It seems that ICT entered medical technologies at a glacial pace 
We calculate all of the possible variations of the backward citation index listed and 
explained in Appendix 3.2. Initially, we compute the simple count of backward citations made by 
medical device patents, grouped by the application authority where the application was filed: the 
Swiss National Patent Office, the European Patent Office (EPO), the US Patent Office 
(USPTO) and the World International Property Rights Organization (WIPO). For purposes of 
simplicity and brevity, we present here only the results obtained with USPTO citation data.17 
                                                          
 
17 The USPTO legislation, in particular, the “duty of candor,” enhances the disclosure of prior art by inventors. See 
Appendix 3.2 for an overview of the differences in the application and granting processes between the various 
patent authorities. Our results obtained for IPI (Switzerland), EPO and WIPO are available upon request to the 
corresponding author of the paper. 
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The trend of the backward citations of the patents filed at the US Patent Office looks 
complete and seems to provide some information about the interaction between MedTech and 
other technologies.   
In any of our initial estimations, the share of ICT never crosses a 1.5% threshold, nor 
does it appear before 1995. Furthermore Figure 3.218 shows a lack of citations to ICT, even in 
historical periods of great impetus of IC technologies. It seems that – contrary to a general 
feeling shared by both historians of technology and economists of innovation – ICTs entered 
medical technologies at a glacial pace, at least in Switzerland and in the domain of orthopedic 
medical devices. 
 
Figure 3.2: Percentage of US MedTech backward citations to ICT and the first 4 more cited technologies, over the total 
 
These initial results are very surprising. The expectations were to find a quite high 
percentage of ICT technologies as anecdotal evidence, expert interviews, case studies, and 
historical analyses tend to show19. One central highlight from these various informative sources 
is the centrality of ICT integration as an engine for innovation and technological change in the 
medical device sector during the last 10 years.  However, the figures above show how backward 
citations to ICT are very sparse. The technologies that appear to be important for medical device 
innovations are mostly the same in all of the three groups (but with different values). 
                                                          
 
18 All the graphs related to the backward citations count are calculated as percentage of each technology, over the 
total amount of backward citations  
19 Transcripts of the interviews are available upon request (with undisclosed interviewee s names) 
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“Pharmaceuticals” began to be strongly present in the MedTech citations from the beginning of 
the 1990s. “Mechanical elements,” “Machine tools,” and “Other special machines” appear to be 
important technologies for MedTech in all of the three groups. A few other technologies have 
very low values (approximately 1.5%), such as “Electrical Machinery Apparatus and Energy,” 
“Measurements,” “Other Consumer Goods,” and “Surface Technology, Coating.” Using this 
method, the average percentage of citations involving MedTech to MedTech is 73%. 
To explore these puzzling findings further, we calculate the backward citation index, 
grouping MedTech patents and their citations by family20 (Figure 3.3).  
 
Figure 3.3: Percentage of DocDB MedTech backward citations to ICT and the first 4 more cited technologies  
 
Using families, the amount of backward citations is higher than in previous exercises; 
therefore, it is less likely for us to find null values in the trends. 
Despite the above finding, the new results do not add any information. The share of 
backward citations to ICT is less than 2.5%. This point coincides with the initial pick in 1995. 
After the pick, the trend stabilizes at around 0.5%. The most cited technologies are the same 
ones found in previous figures. There is slightly increasing importance of “Biotechnology,” 
“Macromolecular Chemistry,” “Electrical Machinery,” “Measurement,” and “Other Consumer 
                                                          
 
20 Different approaches are possible for grouping patents and citations into families (Bakker et al., 2014). For our 
purposes, we decided to use the so-called DOCDB family method.  
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Goods,” but their values are not high enough to overcome “Mechanical Elements,” “Machine 
Tools,” “Other Special Machines,” and “Pharma.” 
Finally, we calculate backward citations using the citations’ origins (Figure 3.4). We 
consider separately the citations that were referenced by the applicants and the ones referenced 
by the patent office, who applied at the US Patent Office21, and we calculate the backward 
citations. With this method, the average percentage of MedTech to MedTech citations is 71%. 
 
Figure 3.4: Percentage of MedTech backward citations originated by the applicant to ICT and the first 4 more cited 
technologies  
 
In this case, the result changes significantly in terms of share values.  
Looking at these results, Chemistry is the most-cited sector. The percentage of 
backward citations reached by “Pharma” is impressive, reaching 13% and with an average 
around 7%. The backward citations to Electrical Engineering, on the other hand, do not even 
reach 1%. In the Instruments sector, only citations to “Measurement” appear to have some 
impact in a short period of time, but with an average of less than 2%. As in previous results, the 
Mechanical Engineering sector, and in particular, “Mechanical Elements,” “Other Special 
Machines,” and “Machine Tools” has a strong presence in the citations. Other fields do not 
show particularly significant trends. 
Based on these findings, the innovativeness of the medical device sector seems to rely 
truly on “traditional connections” such as Mechanics and Pharma.  Table 3.1 suggests that the 
                                                          
 
21 See Appendix 3.2 for more details. 
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potential of MedTech to regenerate through integrating new ICT applications is very low, and 
medical technology innovations seem to rely much more strongly on “non GPT” and more 
traditional technologies. 
Top ten cited Technologies 
1 MedTech 
2 Mechanical Elements 
3 Pharmaceuticals 
4 Machine Tools 
5 Other Special Machines 
6 Macromolecular Chemistry, Polymers 
7 Materials, Metallurgy 
8 Biotechnology 
9 Surface Technology, Coating 
10 Handling 
Table 3.1: Top ten technologies cited by Medtech 
 
To summarize, we have used different methods of calculation regarding the backward 
citation index of MedTech in order to measure the dynamics of ICT integration. Our finding 
shows that ICTs do not play a central role. It seems to us that such a result is inconsistent with 
the massive (qualitative) literature and anecdotal evidence on this topic. In the next paragraph, 
we investigate more in-depth the reason for such a discrepancy between what the methods based 
on backward citation can demonstrate, and what the vast qualitative literature is telling us. 
3.6 Qualitative overview of the problem 
In order to better understand our results, we have randomly selected 10 patents within 
our sample, and we have analyzed their technological content, technological classification and 
backward citations. We chose for our qualitative example the EPO patent titled “Surgical 
Cassette”22 (see Graphic 3.1). 
                                                          
 
22 EP1787606A1  
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Graphic 3.1: Qualitative description of the problem: The Surgical Cassette patent 
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This patent has two IPCs, and both of them identify a medical device. Interestingly, in 
the abstract, the description of the invention states that it contains “Radio frequency 
identification…and pressure sensors, having a mean for automatically identifying unique 
information specific to an individual cassette which may affect operation of the surgical 
system…” 
We expect to find at least some backward citations to ICT technologies. When we look 
at the backward citations, we find 8 patents. None of them has a classification (IPC) identifying 
technologies other than medical device technology. Just three out of the 8 patents have multiple 
IPCs – that is to say, they combine the medical device IPC with another IPC (see the three 
patents in color at level 1). The first one combines an IPC related to a medical device with other 
two IPCs:  F04B43/12, defined as “Machine, pumps having flexible working members having 
peristaltic action [Mechanical Elements]” and F04B49/02, defined as “Control for machine pumps 
(stopping, starting, unloading) [Mechanical Elements].” The second patent combines the medical 
device IPC with G02B23/24, defined as “Fiberscope, instruments for viewing inside of hollow 
bodies [Optics].” The third patent combines the medical device IPC with G06K 7/10, “Methods 
or arrangements for sensing record carriers by electromagnetic radiation, e.g., optical sensing; by 
corpuscular radiation [Computer Technology]”. 
Surprisingly, only one of the four “other” IPCs is related to ICT.  
We decided to look more in detail at the three patents that exhibit a combination of 
different technologies in their classification. When we look at the backward citations of these 
three patents (level 2 in graphic 3.1, corresponding to the second stage of backward citations), 
we find that the technological classifications of the patent cited at level 2 describe in better detail 
the content of medical device innovation under consideration (the Surgical Cassette). 23 
The observation of second-level backward citations applies also to the other patents 
randomly selected.  
In order to better understand the phenomenon observed, we interviewed two patent 
examiners currently working at WIPO. We showed them the patent on the “Surgical Cassette,” 
and we asked them to tell us what kinds of citations they were expecting to find. Their answer 
was very straightforward: “We expect to find citations to previous medical devices using a similar 
technology.” They confirm that patent examiners do not add references of what they view as 
                                                          
 
23 In fact, we found patents whose aim is to identify drugs based on the barcode, or devices for conversion from a 
pharmaceutical identification number to a standardized number, or a peristaltic pump having the means for reducing 
flow pulsation. 
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“common knowledge,” even if this “common knowledge” is still protected by a patent. Thus, in 
the specific case of the “Surgical Cassette” patent, ICTs were not included in the backward 
citations because, in the view of the examiners, those specific ICT components did not feature 
any impressive inventive step for the invention under consideration. It seems that if a technology 
has already been used to produce a new combination, the inventive step had already been 
recognized in former patents, and it is therefore not cited any more. It is treated by examiners as 
“common knowledge.” 
From this argumentation, we can argue that citations are inserted more in relation to 
the invention claims, than to the technological content of the application. MedTech’ claims lays 
in sector such as Pharma, Mechanics and MedTech itself while all- purpose technologies, as ICT, 
are left out.  
Consequently, we state that the problem in finding backward citations to ICT is 
twofold:  
1) When the backward citation approach is reduced to the “first stage,” a 
large part of the external knowledge that explains the focal invention (and that can be 
identified in the second stage) remains unobserved. 
2) As the process of knowledge integration and recombination evolves, the 
knowledge used and absorbed at the early stages become invisible. It does not 
disappear as a substance, but it becomes invisible, or at least very hard to observe. 
3.7 Are backward citations still the right method to measure GPTs, generality and 
knowledge spillovers? 
Recently, scholars have started to discuss the validity of the backward citation index as a 
proxy for technological knowledge spillovers (Alcacer et al., 2009; Roach and Cohen, 2013). 
There is increasing awareness that the very way citations are inserted through an examiner’s 
professional practices is neither systematic nor stable. The authors pointed out the potential 
mistakes generated by observation and measured those that are limited to first-stage backward 
citations. To identify the technological impact of a patent on another one, Trajtenberg et al. 
(1997) add to the classical count of citations a weighted count24 of second-stage citations (strictly 
speaking, the backward citations of the patents cited by the focal patent). In this way, the authors 
aim to capture the technological impact of all previous knowledge regarding a specific patent. 
Frequently, patent citations are used additionally as a proxy for the value of a patent. With this 
                                                          
 
24 The weight is fixed and equals 0.5. 
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aim, Von Wartburg et al. (2005) create a network of citations. The nodes of the network 
represent the patent applications, while the ties stand for the citations that connect the patents. 
The authors look not only at the direct ties of the network (the classic backward citations), but 
also at the second stage of citations, namely the indirect ties, weighted. Han and Park (2006) also 
propose a new method to measure knowledge flows between industries. Using patent data and 
citation data, they build a network of knowledge spillovers, represented by two matrices: the first 
one represents the amount of knowledge belonging to an industry, and the second one 
represents the degree of interaction between industries. Therefore, the knowledge flows are 
represented as the product of the two matrices. They show that the ICT-based sector turned out 
to be the most active actor in the network of knowledge flows. ICT both spreads and absorbs 
knowledge to and from other sectors. The authors also show the intense link between the ICT-
based sector and more traditional ones such as manufacturing. Finally Jaffe and De Rassenfosse 
(2016) underline the lack of literature in regard to the process of citations across different sectors 
and hypothesize about the possibility of the existence of differences in the citing process. 
In conclusion, the literature is starting to reveal the validity and robustness of the 
standard methods and seeks new methods for understanding knowledge spillovers. What 
emerges is that knowledge flows can be traced more properly and precisely while looking not 
only at the first stage of patent citations.  
3.8 Our methodological proposition - 1: Measuring the speed of adoption 
Our approach is based on the concept of “speed of adoption.” Our hypothesis is the 
following: the faster the speed of adoption of a new technology z, the faster this new technology 
z becomes public knowledge, the faster it disappears from the first stage of backward citations, 
and consequently, it becomes invisible or unobservable. From an empirical point-of-view, this 
phenomenon leads to an underestimation of the knowledge recombination between the user 
sectors and the new technology z, which is rapidly adopted. In fact, if the new technology z is 
rapidly diffused in the user sectors, it will be massively included in the references of the first 
round of the patents of the user sectors using the new technology z. This will lead us to think 
about this technology z as “given,” and it will not be necessary to cite it any more in subsequent 
inventions. We argue that the speed of adoption regarding a given new technology z may 
influence the capacity of the backward citation index to capture the real intensity of technological 
knowledge spillovers. For technologies with a high speed of adoption, the materialization of 
spillovers happens through the integration of public knowledge rather than of patented 
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technologies. This type of knowledge spillover is more difficult to measure by means of 
backward citations.    
To calculate the speed of adoption, it is necessary to calculate the rate of adoption 
(RA z,t). It is the percentage of firms that, at a certain point in time, decide to adopt a new 
technology over the total number of firms present in that moment on the market (Batz et al., 
1999). 
Thus, the speed and rate of adoption will be calculated as: 
(1) ?peedAdoptionz,t=
RA z,t
tz?t1…T?      (Equation 3.2) 
(2) Rate adoptionz,t= ? 
NCA,  z,t
NPA, z,t
?      (Equation 3.3) 
 
where t is the year of the birth of a new technology, z is the technology, ???????  is the 
number of firms adopting the new technology z, and NPA, t,z is the total number of potential 
adopters (including those who have already adopted z). tz?t1…T? is the time occurring from the 
moment in which the new technology is available since the moment in which it was adopted.  
We use both the standard IPC classification and the sector classification (technology 
field)25, and we generalize the formula: instead of firms that adopt a technology, we calculate the 
numbers of sectors that adopt a technology. The technology z is identified as the first 4 digits of 
the IPC, and the time t is the priority date of the birth of the invention (priority date). NCA, t, z  is 
the number of sectors adopting the new technology z and has been calculated as the number of 
cumulative distinct sectors who cite (backward) the technology z at time T.  NPA, t,z, the number 
of potential sectors adopting the new technology z at time T, has been calculated as the total 
number of distinct sectors that are present on the market at the time of the invention t26.  We 
decide to take a fixed number of potential sectors in order to have the same “distance to walk” 
for all technologies; in this manner, different results will be comparable. Finally, tz?t1…T?, the 
time occurring from the moment in which the new technology is available since the moment in 
which it was adopted, is calculated as the lag of time between the priority date of the invention 
and the priority date of the patent of the user sector, accordingly (Criscuolo and Verspagen, 
                                                          
 
25 See Appendix 3.1 for more details. 
26 The number of sectors present on the market is fixed and is 35, because the sectors in the PATSTAT 
technological classification are 35 in total. 
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2008; Gay et al., 2005)27. The calculation was computed on two different application authorities: 
USPTO and EPO. We obtained a random sample of patents, without caring about the specific 
country of origin, in order to have a sample as heterogeneous as possible. We choose 100 patents 
for each IPC (4 digits). The total amount of patents is 104963 for EPO and 125789 for USPTO. 
Then we look at the citations received by these patents up to this moment in time (2015). The 
aim of this exercise is examine, for each invention, how many sectors the invention was able to 
touch, and in how much time. Then, we compute an average speed of adoption per year, in order 
to see whether a particular technology has changed its speed of adoption over time. 
The results show that, over time, the speed of adoption regarding different technologies 
remains quite constant. In order to make the results more readable, we translated the IPC into 
the sector classification28, but only with the aim of understanding which kinds of technologies are 
represented by the IPC codes. Some technologies have a slightly increasing speed of adoption 
over time, such as  technologies related to “Environmental Technology,” “Nanotechnologies,” 
“Basic Communication Processes,” “Other Special Machines,” or “Pharmaceuticals.” Other 
technologies show a decreasing speed of adoption, such as those related with “Food Chemistry,” 
“Machine Tools,” or “Measurements.” The technologies related to “Telecommunication” 
inventions represent an exception in terms of the constancy of the trend over time: they reached 
a peak in 2002, increasing six times its usual speed. The differences in the speed of adoption 
among the different technologies can also be quite large. In Table 3.2, we report the list of 
technologies grouped by the 35 sectors in order of decreasing speed of adoption. We see that the 
fastest technologies to be adopted are those in “Nanotechnology” and “Computer Science,” 
followed by “Surface Technologies” and “Audio Visual Technology.” 
 
 
 
 
                                                          
 
27 Some authors argue about the validity in using the grant date instead of the priority date of the patent to calculate 
the citation lag (Metha et al., 2010). The reason is related to the different timing that passes between the application 
and the granting, which can be due to different reasons (patent offices, technology, complexity, and the patent 
examiner). 
28 The sector classification is provided by Table Tls 221 of PATSTAT. For more detailed information, please see 
Appendix 3.1. 
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Technologies Speed of adoption  
Micro-structural and Nano-technology 3.51278552 
Computer Technology 3.29454233 
Surface Technology, Coating 3.1737498 
Audio-visual Technology 2.99461899 
Optics 2.95263987 
Measurement 2.95142554 
Other Special Machines 2.75183467 
Semiconductors 2.69498699 
Telecommunications 2.6269757 
Control 2.6219856 
Chemical Engineering 2.56481576 
Materials, Metallurgy 2.51757247 
Other Consumer Goods 2.45011299 
Thermal Processes and Apparatus 2.44560092 
Analysis of Biological Materials 2.3537335 
Environmental Technology 2.32940599 
IT Methods for Management 2.30342264 
Machine Tools 2.27040347 
Textile and Paper Machines 2.23274166 
Basic Communication Processes 2.17644449 
Furniture, Games 2.15454082 
Medical Technology 2.15130527 
Handling 2.13123476 
Macromolecular Chemistry, Polymers 2.11806198 
Civil Engineering 2.11774589 
Mechanical Elements 2.11421272 
Transport 2.06314635 
Basic Materials Chemistry  1.87971643 
Engines, Pumps, Turbines 1.82687641 
Electrical Machinery, Apparatus, Energy 1.68661383 
Digital Communication 1.5747299 
Biotechnology 1.43882896 
Organic Fine Chemistry 1.40724125 
Pharmaceuticals 1.20386883 
Food Chemistry 0.04770575 
Table 3.2: Absolute speed of adoption of different technologies 
 
In Table 3.3, we show, for each technology, the average time after which a patent is not 
cited any more. This variable is calculated as the difference between the year of the last citation 
(priority year of the patent citing the patent in our sample) minus the year of the priority date of 
the focal patent. Not surprisingly, the technologies that disappear sooner are those with a higher 
speed of adoption.  
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Avg(time) Technology field 
4.9697 Micro-structural and Nano-technology 
5.3671 Computer Technology 
5.6977 Basic Communication Processes 
6.1091 Optics 
7.1202 Telecommunications 
8.1267 Biotechnology 
9.3368 Digital Communication 
9.3485 Semiconductors 
9.5807 Audio-visual Technology 
10.3462 Measurement 
10.3495 Surface Technology, Coating 
10.477 Textile and Paper Machines 
10.5313 Basic Materials Chemistry  
10.566 Organic Fine Chemistry 
10.6859 Other Special Machines 
10.7518 Control 
10.8847 Thermal Processes and Apparatus 
11.2423 Mechanical Elements 
11.2866 Handling 
11.2868 Environmental Technology 
11.2901 Macromolecular Chemistry, Polymers 
11.3465 Chemical Engineering 
11.3738 Materials, Metallurgy 
11.43 Other Consumer Goods 
11.4327 Engines, Pumps, Turbines 
11.4358 Machine Tools 
11.4726 Transport 
11.7872 Analysis of Biological Materials 
11.9011 Civil Engineering 
12.0888 Pharmaceuticals 
12.3832 Furniture, Games 
12.4259 IT Methods for Management 
12.9483 Food Chemistry 
13.2367 Medical Technology 
16.7391 Electrical Machinery, Apparatus, Energy 
Table 3.3: Average time after which a patent is not cited any more 
 
Thus, patents in technologies such as “Nanotechnologies” and “Computer Science” are 
the fastest to be adopted and the fastest to disappear from the citation references. 
 However, are they also the technologies that are able to reach a large amount of other 
sectors? In Table 3.4, we see that this is the case. Again, an invention in “Nanotechnologies” is 
able to be absorbed by, on average, 5 other sectors, while an innovation in “Computer 
Technologies” is able to reach 4 other sectors.  
Chapter 3: How traditional medical technologies integrate ICT: a new methodological approach  
49 
 
Avg(max_num) Technology field 
5.0152 Micro-Structural and Nano- technologies 
4.91 Computer Technology 
3.8328 IT Methods for Management 
3.547 Macromolecular Chemistry 
3.2422 Basic Materials Chemistry  
3.2305 Surface Technology, Coating 
3.155 Materials, Metallurgy 
3.116 Environmental Technology 
3.1155 Chemical Engineering 
3.0888 Pharmaceuticals 
3.049 Control 
2.9167 Biotechnology 
2.8918 Measurement 
2.8897 Food Chemistry 
2.7967 Semiconductors 
2.7489 Optics 
2.6892 Medical Technology 
2.6827 Audio-visual Technology 
2.6375 Telecommunications 
2.6336 Other Consumer Goods 
2.5842 Digital Communication 
2.5757 Other Special Machines 
2.5544 Thermal Processes and Apparatus 
2.5535 Organic Fine Chemistry 
2.5322 Textile and Paper Machines 
2.5308 Analysis of Biological Materials 
2.5261 Basic Communication Processes 
2.5217 Electrical Machinery, Apparatus, Energy 
2.4343 Machine Tools 
2.2934 Mechanical Elements 
2.2879 Engines, Pumps, Turbines 
2.2859 Furniture, Games 
2.2083 Handling 
2.1462 Transport 
2.1365 Civil Engineering 
Table 3.4: Average number of sectors reached by any technology 
 
These results suggest that technologies do not all behave in the same way when 
interacting with other sectors. As a consequence, the knowledge spillovers of different 
technologies cannot be expressed in their totality by using the backward citations of patent data. 
Some sectors such as “Computer Science” and “Micro-structural and Nano-technologies” are so 
fast in being adopted by other sectors that they also tend to disappear very quickly from the 
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history of prior art. These results are consistent with previous analyses (Hall et al. 2001; Metha et 
al., 2010). The findings of these analyses show that “Computer Science” is cited more quickly 
than any other sector, followed by “Electrical and Electronics” and “Chemicals.”  
If we come back to the results presented in Figure 3.2 on the backward citations of 
MedTech to 5 sectors, we can now observe that among the 5, Pharma technologies are both the 
most cited by MedTech and are also the slowest in terms of speed of adoption (Table 3.2).  
Based on this qualitative and quantitative evidence, it seems clear that the usual method 
of backward citations to measure the integration of GPT into a given technological field is not 
very relevant, since the most powerful GPTs (in terms of speed of adoption) are also those that 
disappear from the citations and become public knowledge most quickly. We therefore propose 
a new method to calculate backward citations.  
3.9 Our methodological proposition - 2: Application 
In the example of the Surgical Cassette previously presented, we found that just three 
out of the eight cited patents have a medical technology IPC combined with some other 
technology. Thus, we look at our entire sample of medical device innovations in order to 
calculate how many patents have the same structure to see whether this technological structure 
stands. We find 1012 patents that have a combination of different IPCs29, about 17% of the total 
patents in our dataset. When we look at the backward citations of our sample, we find that the 
total number of backward citations is 26467, of which 4194 are patents with a combination of 
different IPCs, 3601 are patents that belong entirely to another field, and the remaining 18672 
are medical technology patents. When we look at the origin of the 3601 patents that belong to 
another field, we find that in 84% of the cases, these citations are made by medical device 
patents with a combined IPC. In only 16% of all cases, a patent classified entirely as “medical 
technology” cites a patent of another field. Consequently, we can differentiate two cases: the first 
one occurs when the focal patent is a pure medical technology invention (all of its IPCs are 
medical technology). The second one occurs when the focal patent has a combined IPC, so it has 
a medical technology IPC, combined with some IPCs of other sectors. When we find a patent 
that has a combination of IPCs, we proceed to the normal calculation of the backward citation 
measure. The novelty of our method relies on the treatment of those patents that are entirely 
classified as medical technology (such as the Surgical Cassette proposed in the qualitative 
                                                          
 
29 With respect to a “combination of different IPCs,” we mean those patents that have a combination of different 
technologies, for example, A61N (Electrotherapy…) and H02G (Installation of Electric Cables…). 
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example). In this case, the calculation of the first stage of backward citations is followed by the 
calculation of the second stage of backward citations. We perform the second stage citations 
only for the patents with pure MedTech classification, in order to avoid the overestimation of 
the count of backward citations to other technologies. In fact, as shown before, these patents 
count only for the 16% of the citations to other technologies, meaning that the technologies on 
which they are built are already had been used by other MedTech patents.  
The second stage citation is then weighted by the size of their family in order to 
minimize the effect of big families. Thus, if a cited patent belongs to a family with 10 patents, its 
weight will be 0.1. The decision to use the inverse of family size is due to the fact that families 
have very different sizes, which has clear implications on the probability of being cited. In fact, if 
a patent belongs to a family with a size of 20, it is more likely to be cited by a patent that is part 
of a family of two patents.  
The total number of backward citations will be calculated as: 
Total backward citation patentito technologyz
???? backward citation of all MedTech patents?
??weighted by family size 2nd stage backward citations of patent with"pure"MedTech IPC? 
(Equation 3.4) 
We propose the calculation of a new method, grouping the focal patents by different 
application authorities, and we set the weight so that it reflects the family of the citing patent. 
As in session 3.5, for purposes of simplicity and brevity, we present here only the 
results obtained with USPTO data30. The next figures present a comparison between the 
standard method of backward citation and our method for a range of technologies that MedTech 
patents are supposed to cite. We show successive citations to Chemistry, Electrical Engineering, 
ICT, Instruments and Mechanical Engineering. 
In terms of Chemistry technologies (Figure 3.5), we see an increase of “Surface 
Technology, Coating,” both in the absolute value of backward citations directly to this 
technology and in the consistency of the trend (there are no null values as before).  
                                                          
 
30 Additional analyses are not reported, but are available upon request. 
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Figure 3.5: Comparison between MedTech backward citations to Chemistry; classical measure vs the new method – 
USPTO 
 
With respect to the technologies grouped in Electrical Engineering, (Figure 3.6), 
“Electrical Machinery, Apparatus and Energy” gains a more stable trend, even if the values are 
still very low (average 1.2%). 
Chapter 3: How traditional medical technologies integrate ICT: a new methodological approach  
53 
 
 
Figure 3.6: Comparison between MedTech backward citations to Electrical Engineering classical measure vs the new method 
– USPTO 
 
Also, the technologies grouped in ICT gain a stronger trend. The effect of ICT on 
MedTech starts approximately in 1990 and, compared with the classical calculation, increases in 
its values (Figure 3.7). It is worth to notice that the classical measure shows in one period (1996) 
a high value of backward citations to ICT. It seems that in 1996, when ICTs began to be present 
in everyday life, MedTech started to interact intensively with for the first time.  
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Figure 3.7: Comparison between MedTech backward citations to ICT; classical measure vs the new method – USPTO 
 
Interestingly, in Instruments, “Measurements” gains a solid trend and increases 
significantly in its values (Figure 3.8). In the classical calculation, “Measurement” has never 
appeared to be important for MedTech, while now its values are high enough that it cannot be 
negligible.  
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Figure 3.8: Comparison between MedTech backward citations to Instruments; classical measure vs the new method – 
USPTO 
 
The impact of ‘Mechanical Elements” and “Machine Tools” remains noteworthy 
(Figure 3.9). Moreover, the new figure better identifies the time periods in which “Mechanical 
Engineering” is crucial for MedTech, namely from the 1980s until the beginning of the 1990s to 
the present. 
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Figure 3.9: Comparison between MedTech backward citations to Mechanical Engineering; classical measure vs the new 
method – USPTO 
 
As in Figure 3.10, the new index makes the effect of ICT comparable with that of the 
other strong technologies of MedTech.  
 
Figure 3.10: US MedTech backward citations to ICT and the first 4 more cited technologies- NEW METHOD 
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When we calculate the percentage points of variation between the classical calculation 
(we took the calculation by application authorities) and the new method, we see that the highest 
variation regards the technologies that were already very important for MedTech, namely 
“Pharma”, “Mechanical Elements,” “Machine Tools,” and “Other Special Machines.”  
“Measurements” goes together with “Computer Technology.” This result is very important for 
the truthfulness of our measure. In fact, we were focusing on the behavior of ICT; however, our 
measure brings up all of the technologies important to MedTech that are so fast that they 
disappear more quickly than others. In fact, “Measurement,” which together with ICT gains an 
important role in technological knowledge spillover activity, is in the 6th position in terms of 
adoption speed. 
To further support the validation of the new measure, we observe that there are a few 
technologies (eight in total) that have negative variation. These technologies are the ones that 
also had a percentage below 1% (e.g., “Food Chemistry,” “Environmental Technology,” “IT 
Methods for Management”) in the classical methods. 
To conclude, we see that those technologies that were clearly identified as useful for the 
growth of MedTech innovation in the classical measures are confirmed with the new measure. 
The scope of the new measure is to add information that otherwise would be lost, due to the 
different adoption speeds of the technologies.  
A final point to be discussed is related to the number of different stages to compute to 
obtain the complete information on knowledge spillovers. In order to understand until what 
stage of backward citations we have to calculate weighted citations, we try to go further in the 
calculation of the third stage. In Table 3.5, we report the results of the first three stages of the 
patent taken as an example, the Surgical Cassette.31 
                                                          
 
31 The three stages are not weighted in Table 3.1. 
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Table 3.5: First three stages of backward citations, “Surgical Cassette” 
We can see how the second-stage citations capture the real nature of the invention 
more carefully. The share of backward citations to Computer Technology rises from 5.5% until 
13%. Also, the percentage of Engines and Pumps rises by 4 points. Another important change is 
the slight decrease of Optics in favor of the adjunction of new technologies, such as “Audio 
Visual Technologies,” “Measurement,” and “Controls,” which perfectly describe the invention, 
but which were not present in the first-stage citations. There is an addition of three other 
technologies cited, with a very low percentage: Basic Materials, Machine Tools and Mechanical 
Elements. Of these three technologies, all of them are actually the top 10 technologies cited by 
MedTech, so in any case, they reinforce a trend that was already very clear, and they cannot be 
considered as mere noise. 
The third stage adds an incredible amount of other technologies, with a general 
decrease in the share of all technologies. We believe that the third stage, if taken into account, 
would not even add noise because the citations are spread over 22 technologies; moreover, 
considering that they would have been weighted even more strongly than the one in the first 
stage, their effect would disappear completely. 
First stage Second stage Third stage 
% Field % Field % Field 
5.56% Computer 
technology 
3.77% Audio-visual 
tech. 
0.23% Analysis of biological materials 
5.56% Optics 13.21% Computer tech. 2.53% Audio-visual technology 
83.33% Medical technology 3.77% Optics 0.12% Basic communication processes 
5.56% Engines, pumps, 
turbines 
1.89% Measurement 0.12% Basic materials chemistry  
  5.66% Control 0.35% Biotechnology 
  54.72% Medical tech. 2.42% Chemical engineering 
  1.89% Basic materials  10.24% Computer technology 
  1.89% Machine tools 7.25% Control 
  9.43% Engines, pumps, 
t. 
1.04% Digital communication 
  3.77% Mechanical 
elements 
0.12% Electrical machinery, apparatus, 
energy 
    8.77% Engines, pumps, turbines 
    0.23% Environmental technology 
    0.81% Furniture, games 
    4.83% Handling 
    2.19% IT methods for management 
    1.15% Machine tools 
    0.12% Macromolecular chemistry, 
polymers 
    0.12% Materials, metallurgy 
    4.37% Measurement 
    2.65% Mechanical elements 
    36.82% Medical technology 
    0.58% Optics 
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3.10 Conclusion  
The importance of knowledge spillovers for economic growth is universally recognized. 
The way in which technological knowledge spillovers can be measured has been a hot topic in 
the economic literature. In this work, we attempt to track the technological knowledge spillovers 
from one of the recognized General Purpose Technologies, ICT, toward the medical device 
sector. In order to accomplish this task, we use patent data, and in particular, we propose a new 
formulation of the index of backward citations. From Hall et al. (2001), the calculation of patent 
backward citations has been the most popular way to capture knowledge displacements. 
The aim of this work is to shed a light on the different behavior of the backward 
citations across technologies. We need to keep in mind that citations are inserted in order to 
explain the claims of a patent, in other word only the most innovative part. This brings already 
some issues for the scholars aiming to measure knowledge spillovers through citations. Backward 
citations do not reference to any technological details included in the new patent application. 
More than this, we notice that also the speed at which a technology is adopted can influence the 
measure of knowledge spillovers using backward citations. In order to test this idea, we conduct 
both a qualitative and a quantitative analysis on a sample of medical device patents.  We argue 
that those technologies with a higher speed in being adopted are easier to understand and use, 
and for this reason, they are widely adopted from the first moment they appear on the market. 
The consequence is that they disappear faster from the list of references in the patent legal data 
because they become “common knowledge” more quickly. We calculate the speed of adoption 
of each technology, the time after which the technology has not been cited any more, and the 
amount of a sector that each technology is able to reach. The results show that technologies with 
a higher speed are also those with a higher capability of being adopted by different sectors, and 
those that disappear first from the list of patent backward citations. Our belief is that this 
dynamic introduces the difficulty of correctly tracing knowledge spillovers from the “fastest” 
technologies, such as ICT or Nanotechnologies.  
We propose a modification of the original measure of backward citations that yields this 
new finding. It is based on the calculation of the weighed second degree of backward citations. 
When we add the second degree of backward citations to the classic one, we see how the 
percentage of the core technologies persists, with the addition of the technologies that were 
invisible beforehand, but that are actually important for innovation in the sector. 
The implications of our work are significant for the literature that aims to grasp the 
technological spillovers between different fields. Our results suggest that it is important to 
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carefully analyze the dynamic behavior of different technologies in order to capture existing 
connections more precisely. 
There are possible improvements related with this work. It would be interesting to 
study the speed at which a technology reaches a certain fixed number of sectors, to understand 
the probability of recombining a specific sector. This new measure offers the possibility of seeing 
a new emerging stream of technology recombination inside a sector that otherwise would remain 
too difficult to read. 
 
 
Appendix 
Appendix 3.1: The patent technological classifications 
This paper is based on the July 2015 version of PATSTAT, which is the European 
Patent Office database containing information on patent data. Among the various types of 
information, PATSTAT contains data on the technological classification of patent data. 
All of the analyses of this work are performed using International Patent Classification 
(IPC) codes. The IPC codes are used in PATSTAT to identify the technological classification of 
each patent application, and are contained in the PATSTAT table “tls_209_appln_ipc.” The 
technological classification is a hierarchical system of codification. It provides a technological 
area correspondent to the new invention. It entered into enforcement in 1971 after the 
Strasbourg agreement. Since then, it is updated every January. An IPC code is composed of a 
mix of letters and numbers. The first position of the code is always a letter and identifies the 
section. Next, there are numbers and letters that explain in further detail the technological class 
to which the invention belongs. Technically, these subsequent numbers are defined as a class 
(letter of the session plus two digits), a subclass (a class plus a letter), and a group (a subclass plus 
two digits). The IPC divides technology into eight sections, with approximately 70,000 
subdivisions. Each IPC code is clarified by a technical definition (i.e., “G11C 7/24” is “Memory 
cell safety or protection circuits, e.g., arrangements for preventing inadvertent reading or writing; 
Status cells; Test cells”). 
Since 2013, a new technological classification has been added. It has been created by 
Schmoch (2008), and it provides an industrial sector classification. In addition to the classical 
technological classification, it proposes a new level of grouping all patent applications into 5 
sectors and 35 sub-fields. The 5 sectors are: Chemistry, Electrical Engineering, Mechanical 
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Engineering, Other Fields, and Instruments divided in 35 technological fields. Three columns, 
respectively named “TECHNICAL FIELD,” “TECHNICAL FIELD NUMBER,” and 
“TECHNICAL SECTOR,” support the new classification, providing the names of the sectors, 
the names of the fields and the identification numbers of each field. They are contained in the 
PATSTAT table “tls_901_techn_field_ipc,” together with the column of IPC codes that allow 
the user to complete the conversion between the two technological classifications. The 
connection between the two different methods is, in fact, possible by joining together IPC codes. 
For example, the sector Electrical Engineering includes the field “Computer technology,” which 
has a “technology field number” equal to 6 and is associated with IPC codes G11C, G10L and 
all of  G06#, with the exclusion of G06Q. If we match these IPC codes with those provided in 
table tls209_ipc_appln, we can retrieve all of the applications classified as “Computer 
Technology” and proceed, adding all of the useful information for the analysis. 
We have decided to develop the analyses using IPC codes, but to present the results 
using sector classification because the latter classification is more readable than IPC codes (i.e., 
“Computer Technology” is easier to understand than “G11C 7/24”). 
In this work, we wish to track the interaction between Information and Communication 
Technology (ICT) and medical orthopedic devices.  In sector classification, the category “ICT” 
does not exist. Based on the sector description provided by Schmoch (2008) and the definition 
of ICT provided by (Hall et al., 2001), we decided to create our definition of ICT, including four 
technology fields: Telecommunications, Digital Communications, Basic Communication 
Processes, and Computer Technology. 
The identification of “orthopedic” medical devices was conducted via a search for 
keywords inside of each  IPC definition. The keywords were suggested by one of the experts we 
interviewed in order to have a clearer view of the sector. We identify 58 IPC codes: 
  “A61F   2/00,” “A61B  17/16,” “A61B  17/56”, “A61B  17/58,” “A61B  17/60,” 
“A61B  17/62,” “A61B  17/64,” “A61B  17/70,” “A61B  17/72,” “A61B  17/74,” “A61B  
17/80,” “A61B  17/82,” “A61B  17/92,” “A61F   2/28,” “A61F   2/30,” “A61F   2/32,” “A61F   
2/34,” “A61F   2/36,” “A61F   2/38,” “A61F   2/40,” “A61F   2/42,” “A61F   2/44,” “A61F   
2/46,” “A61F   2/50,” “A61F   2/54,” “A61F   2/56,” “A61F   2/58,” “A61F   2/60,” “A61F   
2/62,” “A61F   2/64,” “A61F   2/66,” “A61F   2/78,” “A61F   2/80,” “A61F   5/01,” “A61F   
5/02,” “A61F   5/03,” “A61F   5/04,” “A61F   5/042,” “A61F   5/045,” “A61F   5/048,” 
“A61F   5/05,” “A61F   5/052,” “A61F   5/055,” “A61F   5/058,” “A61F   5/08,” “A61F   
5/10,” “A61F   5/11,” “A61F   5/14,” “A61F   5/24,” “A61F   5/26,” “A61F   5/28,” “A61F   
5/30,” “A61F   5/32,” “A61F   5/34,” “A61F   5/37,” “A61F   5/40,” “A61G   1/052,” “A61G   
1/056” 
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Appendix 3.2: Existing measures for technological spillovers 
In this Appendix, we wish to provide a brief overview of the different approaches 
existing in the literature to measure knowledge spillovers using patent data. 
There are three different ways to measure knowledge spillovers using patent data: 
technology matrices, backward citations, and citation functions. 
Matrices 
The willingness to capture technological knowledge spillovers dates back to 1979, when 
Griliches (1979)  proposed one of the first attempts to generate technological indicators using 
the indirect R&D of a sector to prove that it affects the cross-sector’s knowledge exchange.  
The first method using patent data was proposed by Scherer (1982). He built a matrix 
of technologies exchanges between the producer sector and the user sector. He used patent, 
survey, and R&D data. 
Following the same idea, Putnam and Everson (1994) proposed the Yale matrix. They 
were able to build a matrix of technology exchanges between the producer and user sectors using 
patent data. The Canadian patent office is the only office that provides not only the IPC codes 
for each patent, but also the user sectors. This method has been used by many other authors, 
who investigated whether the Yale matrix was a correct indicator of technological knowledge 
spillovers (Keller, 1997; Kortum and Putnam, 1997; Meijl, 1997). The results show that there are 
two weaknesses related to the Yale matrices. The first one is related to the over- estimation of 
obvious relations, i.e., pharmaceutical products and the medical industry. The second weakness is 
related to the fact that this type of matrix does not measure pure technology knowledge 
spillovers. In fact, it is very likely that the user sector will be asked to pay a fee to use the 
technology covered by the granted patent. 
 Jaffe (1986) and Verspagen (1997) proposed two similar methods, based on the 
“technological perspective.”  The matrix is built based on the technological distance of firms, 
calculated using their technological patenting history. The technological spillovers between firms 
are weighted by their technological distance.  
Function of citations  
In the literature, there are different versions of the citation function. The very first one 
was proposed by Caballero and Jaffe (1993) and was partly redefined by other scholars in 
subsequent years (Hall et al., 2001; Jaffe and Trajtenberg, 1996; Popp, 2002). In general, the 
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probability that a patent cites another patent is a function of three variables: the diffusion 
process, the obsolescence rate, and a parameter based on the characteristics of the two patents. 
The advantage related to this approach concerns the elimination of some of the noise 
that affects the citation probability (i.e., the examiner, the cohort effect, the country effect, etc.). 
Backward citations 
Another measure used very frequently is the index of patent backward citations. This is 
the measure we attempt to improve with our work. 
A patent is a legal document that offers exclusive rights to the owner and to inventors 
in exchange for public disclosure of the invention. In order to prove the novelty and non-
obviousness of any invention, its innovative content must be compared with previous existing 
knowledge. The applicant beforehand and the examiner afterwards list the existing literature 
(patent and non-patent literature) in order to have a benchmark to judge the effective novelty of 
the invention.  
The existing literature is called the list of previous knowledge, i.e., “backward citations.” 
Many attempts have been developed to demonstrate that patent citations are a good measure of 
knowledge flow.  
Jaffe et al. (1993) describe the reason why patent citations are a good means of tracing 
spillovers. Citations can be introduced either by the applicant or by the patent examiner. While 
the citations listed by the applicant should be an actual measure of the awareness of the 
knowledge owned by the inventors, or at least part of it, the citations added by the patent 
examiner are references to prior art that could be unknown by the inventors. Consequently, 
citations are a “very noisy measure for spillovers,” but they are also a very conservative measure, 
in the sense that if some significant results appear, then they must be correct because they were 
able to emerge despite the noise generated by the references added by the patent office. In the 
same vein, Hall et al. (2001) and Duguet and MacGarvie (2005) add  empirical proof to the use 
of backward citations, undergoing surveys to explain the origin of the citations they insert into 
their patents. In both works, the authors find confirmation that backward citations reflect the 
inventors’ knowledge, even if the validity changes with the source and the destination of the 
knowledge transmitted. Finally, Breschi and Lissoni (2001) explain that even if patent citations 
are added both by the inventor and the examiner, they are both valid. The reason is that 
inventors can have a strategic reason not to disclose the prior art, while examiners fill the gap. 
A common method to calculate patent backward citations was simply to count the 
number of prior patents. For any focal patent, the references are counted. However, there are 
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many options that can be added to this simple count. The most common method has been to 
count the number of prior patents, weighed by the depreciation rate for the value of the patent 
(Hall et al., 2005). For each patent citation, much information can be added, such as the priority 
year, or the authority where the patent application was filed or the technological classification 
(IPC).  
Thus, there are numerous choices that must be done in the calculation of the backward 
citation index, based on the information retrievable in PATSTAT.  
In PATSTAT, it is possible to differentiate between the patent and non-patent 
literature. The non-patent literature includes articles, papers, academic works, and presentations; 
in short, everything that is not a patent.  Also, the non-patent literature is used to decide the 
novelty of an invention, but in contrast to the patent literature, it does not have much 
information added to the exemption of a text description of the content. Despite this limitation, 
the non-patent literature has been used to measure the link between science and technology 
(Verbeek et al., 2002). In particular the non-patent literature has been used to measure the value 
of patents, but only in specific sectors, such as chemistry and pharma (Harhoff et al., 2003) and 
the depth and breadth of pharmaceutical research (Brusoni et al., 2005).  
However, above the selection of the different variables requested for a specific analysis, 
“a thorough understanding of patenting practice is needed in order to interpret patent citations 
data properly” (Meyer, 2000). There are many differences in regulations between patent 
authorities that should be taken into account in developing a correct patent analysis. For our 
work, we analyze the differences between the European and US patent offices. The search report 
is the document written by the patent examiner that includes, among other information, the 
technological classification, the approval of the claims, and the missing references to prior art. In 
the US the “duty of candor” promotes the inclusion of as many citations as possible by the 
inventors. Consequently, in the US, two-thirds of the total citations are added by the inventor 
(Alcacer et al., 2009). At EPO, the duty of candor does not exist. On the contrary, the list of 
prior art is optional. An EPO examiner includes most of the citations. Also, the average citation 
count per patent changes between the two patent offices.  The result is that the same measure 
computed from two different data sources can lead to very different results (Bakker et al., 2014).  
Consequently, the origin of citations should also be taken into account. Since 2013, in 
PATSTAT it is possible to identify whether the citations come from the examiner or from the 
applicant. This information helps capture more accurately the cumulativeness of knowledge 
because it becomes possible to distinguish between the knowledge that was added by the 
inventor (or the applicant) from that added by the patent examiner for legal purposes, which can 
Chapter 3: How traditional medical technologies integrate ICT: a new methodological approach  
65 
 
be unascertained by the applicant of the patent (Alcacer et al., 2009; Criscuolo and Verspagen, 
2008). 
The last point to be discussed regards the level of analysis. Many works are limited to 
the patent level (more specifically, the patent application), counting the number of backward 
citations for each focal patent. Others prefer to look at families. There are two types of families: 
DOCDB and INPADOC. The DOCDB family groups all patents that share the same priority 
date; in other words, all of those patents that are exactly the same invention filed in different 
patent authorities. The INPADOC family, instead, has a less stringent definition and includes 
patents that are still protecting the same invention. However, they can also have a different 
priority application (Dernis and Khan, 2004). Again, in this situation, the count of citations can 
be different: one should count the total number of citations of the entire family in order to 
eliminate the risk of bias created by large patent families; otherwise, the count would not be at 
the level of application any more, but the family cited. There are many papers that discuss which 
of the two families is better to use (Bakker et al., 2014). This is not the aim of this paper, so we 
propose the two retrievable in PATSTAT. The count of citations per family can again be 
different: one could count the total number of citations of the entire family; otherwise, in order 
to eliminate the risk of bias created by large patent families, the count would no longer be at the 
level of application, but the family cited. 
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Chapter 4: The Effects of Regulation Change on 
Innovation: The Case of the European Medical 
Device Sector 
(with Fabiana Visentin) 
4.1 Introduction 
According to common wisdom, technological innovation positively contributes to 
economic growth. It represents the engine of the economic development process, providing new 
solutions and opportunities for industries and consumers, and more broadly, improving social 
welfare, ensuring greater consumer abundance, and providing new medical interventions for 
diseases. However, this process is not immune to criticism. People have expressed concern for 
the side effects accompanying those innovations. Environmental problems caused by production 
procedures that do not respect nature, declining workplace conditions, and increased risk levels 
for final users are just some examples of the negative consequences of the frenetic search for 
new technological innovations (OECD, 2009).  
In response to these concerns, since the mid-twentieth century, regulations have been 
introduced worldwide in all sectors to moderate the side effects of technological innovation. 
Economists’ reactions to attempts to minimize the negative effects of technological evolution 
have varied.  Some economists manifest their fear concerning the fact that regulations could 
deteriorate the natural technology growth trend. Others are more inclined to understand “what 
tradeoff our society is willing to make” (Eads, 1980, p. 51) between social and economic benefits 
and the risk of an unconditional technological evolution. The latter debate sheds light on other 
effects to which the regulation can lead, such as a new allocation of resources, risk reduction in 
R&D activities, commercialization of new products or a change in the type of institutions who 
carry out specific research.  
There is little evidence concerning the impact of regulation on the ability of firms to 
innovate (Blind, 2012). Extant studies look at innovation in quantitative terms, e.g., examining 
the number of patent applications (Jaffe and Palmer, 1997; Golec et al. 2005; Popp, 2006) or the 
number of new products introduced (Nemet, 2009). We contribute to the existing literature by 
considering how regulation impacts the content of the innovation activity and the diffusion of an 
invention. 
Our empirical strategy relies on comparing changes in innovative trends in two sectors 
with similar characteristics differing in the fact that one of them has been affected by a rigorous 
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regulation while the other not. In 1993, a stringent regulation, the Directive 93/42/EEC, 
affected the medical devices sector (MedTech) imposing the fulfillment of rigorous safety and 
quality requirements for the commercialization of any medical device. A similar sector in terms 
of patenting activity and actors involved, the mechanical sector, was not affected by any 
additional rules. Exploiting variations in sectorial regulation, we compute differences-in-
differences estimates of the effects of the Directive. That is, we compare changes pre-1993 and 
post-1993 in the patenting behavior of the medical devices sector versus the mechanical sector.  
For our analysis, we use a novel dataset of 543,667 inventions developed in the period 
1980-2012 in Europe, 117,993 in the medical device sector and 425,674 in the mechanical sector, 
respectively.  On one hand, the European medical device sector appears to be an ideal empirical 
setting to act as ‘treated’ in investigating the relationship between sector regulation and 
innovative dynamics. The sector has been affected by more stringent regulation over the years, 
since it includes tools that enter into direct contact with the human body. Nowadays, the actors 
involved in the sector have to fulfill clearly defined safety requirements and quality standards to 
market their products. However, back in the early 1990s, this same sector was mainly 
unregulated. On the other hand, the mechanical sector appears as an ideal ‘counterfactual’, since 
it remains unregulated. The comparison of the two sectors allows us to answer to the question 
“What have been the impacts of the regulation changes on innovation?”  
This paper is part of a broader project investigating the evolution of the medical device 
sector in Europe. In the exploratory phase, which was oriented toward collecting qualitative 
evidence on the dynamics and mechanisms governing the sector, we interviewed the R&D 
personnel involving a random sample of medical device companies based in Europe32. When 
asked about the impact of rigorous rules on their activities, these sectoral actors were aligned in 
claiming that regulations limit the exploitation of their opportunities to introduce new devices.  
“After the ‘90s, as manufacturers of medical devices, we need to conform to the directives and to 
prove that our products are safe and work properly… When I started to work here as Product Development 
Manager, I was pushing my team of engineers to do breakthrough research. I knew that it was easy to launch 
cutting-edge products on the market. Nowadays, we have to fight with a pile of papers… I asked to them to 
be conservative… if they work on improving the existent technologies, it is easier for me to convince the 
authorities that the device is safe. If I ask for the CE mark of a device that has never [been] seen before, it is 
a nightmare to find the appropriate clinical evidence! If I do not get the CE mark, I cannot commercialize the 
product, and all the investments will be lost. I cannot permit that! It’s too risky! I prefer to stay on a safer 
side… Yes, we are still renewing our product portfolio; we are well-known as an innovative company, but we 
                                                          
 
32 For the interviews, we selected the representatives involving firms of different size and age located in Europe and 
specialized in various types of medical device production. Specifically, we conducted phone interviews with the 
CEOs of three multinational companies: the Product Development Managers at four small-medium enterprises and 
the founders of three start-ups. Our interviewees were based in Italy, Germany and France.  
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are not any more exploring the unknown as in the past.” (Product Development Manager, small-
medium French company) 
“During my PhD studies, I developed a device – a sort of mask glasses – reproducing a virtual 
reality in 3D. My initial idea was to use the glasses as a medical tool to help patients who need help in 
rehabilitating from a stroke. These patients could have played in a virtual reality and, [in] doing so, their 
brain cells would have recovered their functions. I launched my own business on the medical direction, but soon 
after I realized that it was really difficult… too many rules! So I thought… What about selling the device as 
a game? This is what I am doing!”  (Founder, German start-up) 
According to the interviews, it is clear that regulations have been viewed as an obstacle 
for innovation. Inventing something from scratch has become too risky, and attempts to 
radically innovate are perceived as more likely to lead to “dud” inventions. As a consequence, 
incremental innovations appear more attractive to firms complying with regulations. In extreme 
cases, inventors have shifted their attention toward less regulated sectors. The first part of our 
work is dedicated to investigating whether the detrimental effects of regulation on innovation, 
anticipated by the qualitative evidence, are confirmed in the patenting process.   
To comply with a regulation means following a set of rules that, in the case of the 
medical device sector, translates to fulfilling a set of safety standards. If that fulfillment is costly 
for inventors, we cannot ignore the benefits of standardization, once achieved. The regulation 
we are analyzing in this paper pertains to European coverage, i.e., countries belonging to the 
European Union are asked to satisfy the same standards in order to commercialize their products 
in the European market. It is clear that a European regulation is an important step to 
guaranteeing the acceptance of products in a broad geographical market. Therefore, we expect 
that this regulation would positively affect the diffusion of an innovation. The idea is that since 
inventors rely on standards that go beyond their national borders, they are incentivized to extend 
the protection of their inventions beyond the national level. The second part of our work is 
dedicated to investigating whether the patent data confirm the expected positive effect of 
regulation on the diffusion of inventions.   
Our analysis shows that, the introduction of the European directive in 1993 induced a 
deviation in the medical devices sector patenting behavior with respect to what happened in the 
mechanical sector: (1) inventions were built on more familiar components; (2) at the same time, 
applicants filed their patents to a larger number of European patent offices than that in the pre-
regulation period.  Our results offer an important contribution to the policy debate on the 
consequences of regulation introduction. 
The rest of this paper is organized as follows: Section 2 provides a brief overview of the 
effects of regulation on innovation; Section 3 describes the medical device sector and its 
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regulation; Section 4 provides an overview of our data; Section 5 presents our main analysis; 
Section 6 summarizes the empirical findings, and Section 7 concludes. 
4.2 The effects of regulation on innovation 
The Organization for Economic Co-operation and Development (OECD) defines a 
regulation as the “imposition of rules by government, backed by the use of penalties that are 
intended specifically to modify the economic behavior of individuals and firms in the private 
sector” (OECD, 1993, pg.73). The effect of regulation on technological change and innovation 
has been a hot topic in the literature for a long time (Ashford et al., 1985; Blind, 2008; 
Herzlinger, 2006; Rothwell, 1980; Stewart, 1981; Verhoeven et al., 2016). Regulations are seen by 
firms as one of the core factors influencing the innovation process. The OECD Directorate for 
Science, Technology and Industry (2009) highlights the direct relation that exists between 
regulation and innovation. Regulations can positively or negatively affect innovative outcomes.  
According to Porter et al. (1995), a regulation can be considered to yield positive effects 
when it fulfills three characteristics: “It must create the maximum opportunity for innovation, 
leaving the approach to innovation to industry and not the standard-setting agency. Then, it 
should foster continuous improvement, rather than locking in any particular technology. Third, the 
regulatory process should leave as little room as possible for uncertainty at every stage” (pg. 100, 
italics is ours). 
There are numerous cases in which regulations have been seen as an opportunity for 
innovation (Porter et al., 1995). Such regulations can be a stimulus for a breakthrough in the 
current technological trajectory. For instance, the introduction of a new regulation can enhance 
the creation of completely new processes or products because it may be too costly to fulfill the 
regulation requirements with the existing technology, and significant technological change is 
required. This was the case for the Act of the Consumer Product Safety Commission, which 
imposed the elimination of chlorofluorocarbons contained in aerosol devices. This imposition 
led to a radical transformation of the process and to a complete renewal of the product: a non-
fluorocarbon propellant was developed to replace the existing technologies that were not 
fulfilling the recommended safety requirements. In other cases, the innovations introduced by 
regulations are less radical. The Clean Air Act, introduced in 1977, is an example of a regulation 
that led to simply incremental innovations. The Act established a daily threshold for mercury 
discharges per firm. Each firm complied with this regulation by slightly modifying their 
production processes and by putting in place solutions that were already known, but not used 
systematically.  
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There are cases for which regulation has been detrimental to innovation.  Grabowski et 
al. (1978) showed how increased supervision of the pharmaceutical regulation in the U.S. had a 
negative effect on innovative activity in this sector. The redefinition of this regulation resulted in 
fewer radical products launched into the market by the pharmaceutical industry. The decreased 
creation of brand new products was accompanied by a high increment in the cost and time of 
R&D activities. Not only was the development of new products more costly, but firms perceived 
increased risk in developing brand new formulas: only one-seventh of the total products that had 
undergone clinical trials were admitted to the market. Similarly, Vernon (2003) found that the 
introduction of a price control policy, i.e., an economic regulation, resulted in decreased R&D 
intensity.  
The above-mentioned examples provide evidence that regulations can have different 
consequences. The results are not generalizable; rather, they depend on the type of regulation, 
the type of industry affected by the regulation, and the availability of easy or existing 
technological solutions for the fulfillment of  norms (Ambec et al., 2013).  
OECD (1997) proposes a taxonomy of regulations in order to better understand their 
possible effects on innovation. Regulations, according to their scope, are classified as 
administrative, economic and social in nature. Administrative regulations have the aim of 
organizing the operational part of markets; economic regulations have the aim of favoring good 
organization of markets; and social regulations have the aim of safeguarding the welfare of 
society and minimizing negative externalities. The first two types of regulations lead to negative 
effects, such as increased barriers to entry and decreased investments in R&D, which are 
counterbalanced by positive effects, such as reduced risk in investments and minimized 
turnovers (Blind, 2012). In general, social regulations have negative consequences by reducing 
innovation due to the high costs of regulation compliance; nevertheless, they have positive 
effects in increasing the diffusion of new technologies.   
Regulations in the medical device sector are classified as social regulations. In the 
medical device landscape, the policy implications of regulations on innovation are still 
controversial. In the past years, the development and complexity of new devices have required a 
careful assessment of their quality and safety. By staying at the technological frontier for medical 
devices, producers have benefitted patients in terms of bringing them relief, making disease 
treatment more effective, and improving their life quality. However, the introduction of 
completely new tools raises doubts related to their level of risk. Thus, for safety and health 
regulations, there is a trade-off between the possibilities of increasing the well-being of society 
and minimizing the side-effect risks of new products. A crucial point in this type of regulation 
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lies in its capability to minimize the information asymmetry existing between producers and final 
users, convincing the latter to use a new product that, fulfilling stringent requirements, is safe. 
In this sector, regulators have acquired more and more importance in providing 
direction to innovative paths. Gelijns and Rosemberg (1994) claimed that “the preferences and 
rules of these various actors ?including regulators? exert an important influence on which new 
technologies will be accepted into practice and how they will be used” (pg. 32).   
“In the mid-1950s growing recognition that ischemic heart disease was becoming the leading cause 
of death, and a major cause of illness, stimulated the interest of the pharmaceutical (and medical devices) 
industry in developing new drugs (and devices). The first beta-blockers (and electrical cardio version devices) 
were introduced by cardiologists in the mid-1960s in Europe. U.S. regulatory policies toward beta-blockers 
(and electrical cardio version devices) were more stringent than in most European countries, and beta-blockers 
(medicines and devices) received approval for angina pectoris only in 1972. In effect, this meant that cardiac 
surgeons who developed new treatment procedures in the United States were able to obtain a competitive 
advantage over cardiologists because their surgical technology did not have to undergo regulatory approval.” 
(Gelijns and Rosenberg, 1994, pg. 41) 
As reported in the quote, regulations can favor or hinder the development of new 
treatment procedures. In this study, we contribute to extant studies on the effect of regulation on 
innovation by analyzing the consequences of introducing Directive 93/42/EEC in the European 
medical device landscape. The next section is dedicated to provide a definition of the directive 
application context and a detailed description of its contents. 
4.3 The Directive 93/42/ECC and its application context 
The directive context of application: A brief overview of the medical device sector 
Quoting the official definition offered by the European Commission, a medical device 
is “any instrument, apparatus, appliance, software, material or other article, whether used alone 
or in combination, including the software intended by its manufacturer to be used specifically for 
diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the 
manufacturer to be used for human beings for the purpose of:  
? Diagnosis, prevention, monitoring, treatment or alleviation of disease; 
? Diagnosis, monitoring, treatment, alleviation of or compensation for an 
injury or handicap; 
? Investigation, replacement or modification of the anatomy or of a 
physiological process; 
? Control of conception; 
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and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its function 
by such means.”33 
Importantly, medical devices are classified according to their risk of use on the human 
body. The classification represents an easy way to distinguish devices, from those that are 
associated with a very high risk and that require very stringent regulations, to those that imply 
low risks and can be launched faster on the market. Classification rules are based on the duration 
of contact with the body (transient, short term, long term), on the degree of invasiveness 
(invasive device, body orifice, surgically invasive device), on the distinction between an active 
and non-active device, and on the type of tissue contact34.  
A peculiarity of this sector is related to the key role played by patients, who do not only 
enter into contact with medical devices during their therapies as users, but also actively 
participate in improving these tools35. The medical device sector is thus a very complex sector, 
and without any doubt, it requires strong regulations that are able to maximize the welfare 
produced by these devices and, at the same time, protect patients from the risk of their use.  
Regulations on medical devices are very different across the world. Thirty percent of all 
countries have a structured framework for regulation; another 30% has partial regulation; and the 
remaining countries are in the process of developing a regulation framework or currently lack 
one (Lamph, 2000). Moreover, regulations also evolve at the same pace at which the complexity 
of the devices is increasing. So far, the literature on regulation in the medical device sector has 
focused on cross-country differences between U.S. regulation and European regulations (Chai, 
2000 and Kramer et al., 2012). The two systems differ in a few aspects: for example, the U.S. 
system is highly centralized, i.e., the Food and Drug administration (FDA) has control of all 
procedures for the admission of a product to the market. On the contrary, European law on 
medical devices has “outsourced” the certification of safety criteria to external entities, called 
notified bodies. Moreover, U.S. regulation has been seen as more stringent, and sometimes this 
has been seen to have a negative effect on the speed of innovation. On the other side, European 
                                                          
 
33 For more details on the definition of a medical device, please refer to 
http://ec.europa.eu/growth/sectors/medical-devices/index_en.htm  
34 For more details on the classification of medical devices, please refer to http://ec.europa.eu/health/medical-
devices/files/meddev/2_4_1_rev_9_classification_en.pdf 
35 Interesting examples of products developed with the active participation of patients are reported in Gelijns, 
Annetine, and Rosenberg. "From the scalpel to the scope: Endoscopic innovations in gastroenterology, gynecology, 
and surgery." Medical Innovation at the Crossroads 5 (1995): 67-96. 
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regulation is faster and less severe, even if some scholars are worried about patient safety 
(Lamph, 2000).  
The directive content: 1993 as the breaking point year for the medical devices sector 
In 1993, the European Union undertook new policies with the aim of opening national 
country borders to people and goods. This required the harmonization of different countries’ 
laws involved in the union.  On January 1, 1993, laws allowing the free circulation of goods 
entered into force. Together with all other goods, medical devices were included in this policy 
change with a specific European directive, called 93/42/EEC on medical devices.  
Before 1993, Europe was very fragmented with respect to the regulation of medical 
devices. The majority of European countries did not have any specific regulations. In fact, only a 
few countries had written legislation suggesting requirements on how to put a device on the 
market. Only three countries, namely Germany, Luxemburg and Greece, had set up a national 
authority to control the market. The role of these organizations was to issue authorizations to 
introduce devices into the market. 
In 1993, this regulation defined standards that all products must follow. First, the 
European Commission introduced the figure of the notified body. Conformity assessment of 
goods to the standards defined by the European Commission requires certification by a notified 
body. These notified bodies are third parties, firms or organizations that have the authority to 
release the EU certification for a product (CE mark), and consequently, its authorization to be 
sold within Europe. A firm can choose any European country to receive the CE mark. Each 
notified body is identified by a unique code, and the list of these notified bodies is published in 
the Official Journal of the European Commission. There could be two types of notified bodies: 
those working during the pre-market stage in order to certify conformity to the standards, and 
those working after the market stage, which have to assess whether a product is respecting the 
requirements once placed on the market. Should there be any breakdown in this process; the 
notified bodies also have the authority to revoke permission to circulate a specific product. 
These notified bodies frequently focus only on a specific class of devices36.  
The class to which a device belongs determines the rules to be applied for its approval. 
For this reason, the manufacturer should know from the very beginning of a product’s 
developmental process the class to which it belongs in order to facilitate conformity assessment. 
                                                          
 
36 Device classes are explained in the paragraph: “The medical device sector: A highly regulated sector.” 
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Independent of the device class, all products must fulfill these three conditions in order 
to be admitted into the market: 
a. Meet all of the “essential requirements,” including information on the 
product, which must be provided by the manufacturer; 
b. Fulfill the reporting requirements of the vigilance system; and 
c. Obtain the CE mark. 
 
Harmonization of the “essential requirements” represents the main change introduced 
by  Directive 93/42/EEC. “Essential requirements” are related to the introduction of a clinical 
evaluation, the introduction of a standardized quality system and of technical files that must be 
provided together with the device (see Annex I Part I, 6a of 93/42/EEC). The evaluation 
provides clinical data related to the characteristics and operation of the device under normal 
circumstances and a description of the possible side effects. The data can be based on clinical 
investigations or published or unpublished reports on other clinical experiences. The evaluation 
of the data must follow a specific procedure, which is crucial for an assessment of the 
conformity of the device. With respect to the introduction of an efficient quality system, it must 
be related as much as possible to the type of product developed. There is no imposition on the 
type of quality system to adopt, but the manufacturer is required to keep track via written 
documentation of all elements, modifications and provisions of the quality system. This quality 
system must also manage the risk analysis, preparation of instructions for use, post-market 
surveillance and reporting to the vigilance system. The notified bodies will control and certify 
that the quality system has fulfilled all of the previous requirements. Another element introduced 
by the regulation is related to technical documentation, which must be provided together with 
the device by the manufacturer. There is a long list of elements that must be included in the 
technical documentation37, and among them are the results of the risk analysis conducted by the 
quality system, evidence of requirement fulfillment and clinical data. The technical 
documentation must be sent to the notified body for conformity assessment. Compared to 
previous national regulations, requests for a formal risk assessment heavily increase the 
responsibility of the manufacturer. For this reason, the European Commission specifies a 
particular harmonized standard in order to develop the risk analysis (see the EN 14971). The 
manufacturer must also supervise the after-market period, maintaining up-to-date information 
                                                          
 
37 Please refer to Directive 93/42/EEC for details. 
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about user experiences; moreover, it is obliged to immediately report any deviation from 
previous documentation to the vigilance system. 
During subsequent years, new directives were added to the 93/42/EEC with the aim of 
refining the criteria of safety that medical devices must attain. For example, the In Vitro 
Diagnostic Device Directive 98/79/EC details the criteria that in Vitro devices must satisfy in 
order to enter the market. At the end of 1998, the mutual recognition agreement (MRA) entered 
into force. This agreement was written with the specific aim of promoting market access and 
fostering the trade of goods between the European Union and other countries such as Australia, 
Canada, Israel, Japan, New Zealand, Switzerland and the USA. The MRA concerns six sectors, 
namely medical devices, electromagnetic compatibility, telecommunications equipment, electrical 
safety, recreational craft, and pharmaceuticals. The MRA was supposed to guide the convergence 
of regulatory frameworks and the harmonization of safety requirements and quality systems.  
However, the MRA has still kept the regulations separate from one another. This means that 
there is no automatic approval of European medical devices in external countries, but there is a 
recommendation by the notified bodies to accept the device. The same applies for external 
medical devices in Europe. Finally, in 2014, after the scandal of the French counterfeit breast 
implants, the EU regulation has become stricter. Despite these additional refinements, Directive 
93/42/EEC marks a watershed in the European context for the medical device sector, 
delineating the boundaries between the period when there was a patchwork of national 
regulatory systems (pre-1993 period) and the period when the regulatory system was harmonized 
across European state members (post-1993 period). For this reason, we decided to focus our 
attention on the 1993 regulation. 
4.4 Data 
In our study, we use patent data in order to trace innovative activities. There are some 
concerns associated with the use of intellectual property files as a proxy for innovative activities, 
especially with respect to the fact that not all inventions are patented; moreover, at the same 
time, there is no one-to-one relationship between a patent document and a marketable product. 
However, patents are still the most common data used to trace innovation (Acs et al., 2002; 
Bettencourt et al., 2009; Hall et al., 2001). In our case, patent data appear as ideal data for two 
main reasons. First, patents allow us to explore the technical content of an invention (Fleming, 
2001; Dahlin and Behrens, 2005). Patent documentation contains detailed information on the 
technical building blocks of each invention. As we describe in the following section, we use the 
technological classification to evaluate the novelty content of each patent. Second, patents can be 
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used to trace extensions of geographical protection involving an invention. We use information 
about patent offices receiving patent applications in order to retrieve the market extension 
protection that an applicant intends to provide for her invention, which we refer to as diffusion 
of the innovation.  
Data for this study come from the July 2015 version of PATSTAT. To gather the data, 
we proceed in three steps. First, we extract the entire list of patent applications filed in the 
medical device sector to the European Patents Office (EPO) or to a national patent office of one 
of the EU 15 state members38 in the period 1980-2012. To identify the patents classified as 
medical devices, we collect the International Patent Classification (IPC) codes associated with the 
corresponding sectorial code39. In the same way, having identified the mechanical tools sector as 
the appropriate unregulated sector to compute differences-in-differences estimates of the effects 
of the Directive introduction, we proceed with the extraction of all the corresponding patents40. 
Second, we assign to each patent the nation corresponding to the first inventor address41. We 
kept a patent in our sample if that address was located in one of the European state members. 
The choice to refer to inventors’ address in assigning a nationality to a patent responds to our 
attempt to minimize the noise generated by ownership changes42. Third, we group together 
patent applications that refer to the same invention according to their DOCDB family43, “the set 
of applications filed in several countries which are related to each other by one or several 
common priority filings’’ (Zunica et al., 2009). In this way, our final database results as a dataset 
at an invention (patent family) level that comprises 543,667 observations spitted between the 
medical device sector (117,993 observations) and the mechanics sector (425,674 observations).   
For our analysis, we use a novel dataset of 543,667 inventions developed in the period 
1980-2012 in Europe, 117,993 in the medical device sector and 425,674 in the mechanical tools 
sector, respectively.   
Before entering in the details of the analysis, in the following section we provide an 
overview of the key features of the medical device and mechanics sectors to guide the reader in 
understanding the choice of two sectors as ideal empirical setting for our analysis. 
                                                          
 
38 We consider as state members the following countries: Austria, Belgium, Denmark, Finland, France, Germany, 
Greece, Ireland, Italy, Luxemburg, The Netherlands, Portugal, The United Kingdom, Spain and Sweden. 
39 Specifically, we use the sectorial codes proposed by Ulrich Schmoch (2008). 
40 For the extraction of mechanical patents we refer to the sectorial code 26, Machine tools.  
41 We replicate the same method used by Almeida and Kogut (1999) in assigning a patent to a specific region. 
42 PATSTAT reports for each patent the current applicant at time t, as it is not possible to easily retrieve if the current 
applicant corresponds to the original one. Data on ownership changes are available in separate documentation, but 
do not cover the entire database.   
43 As a reference family, we used the DOCDB family listed by PATSTAT (for further details on family definitions, 
please refer to Martinez, 2010).  
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The medical device and mechanics sectors: A comparison of their key features  
Even if the first medical devices were built hundreds years ago, the real explosion of the 
sector in Europe happened around the 50’s when the society started to flourish after the two 
World Wars. The vibrant economic growth of the post-war period let many people to afford 
items that before were exclusively accessible to rich people such as cars, ski, motor sports. The 
increased demand for new medical devices was driven by the drastic augmentation of fractures 
due to the use of these items but, more in general, to the diffuse eagerness to ameliorate the life 
conditions. Thus, while pharma conducted impressive discoveries for what concerns antibacterial 
and antihypertensive drugs, the medical device sector was able to develop new devices thanks to 
its unique openness to other fields of discovery (Rosenberg, 1994). Very often, the idea of a new 
device was conceived by surgeons, since they were the ones that first perceive the need (Chatterji 
et al., 2008). Surgeons did not possess the technical competencies to operationalize their ideas, 
and they started to collaborate with mechanical companies capable to transform ideas into 
prototypes. In this way mechanical companies entered the medical device sector. Among other, 
Siemens is an example of company that shifted part of its production toward the medical device 
sector. Table 4.1 reports the main actors active in the two sectors in term of patenting activity 
and show that Siemens is still among the top-10 companies in the medical device sector as well 
as in the mechanics sector. 
Mechanics sector Medical device sector  
Top-10 
company  Company Mechanics 
Country 
of Origin 
Top-10 
company  Company MedTech 
Country 
of Origin 
1 Robert Bosch Gmbh DE 1 Philips Electronics NL 
2 Siemens Ag  AT 2 Siemens Ag  GB 
3 Telefonaktiebolaget Lm Ericsson SE 3 
Procter & Gamble 
Company US 
4 Nokia  AT 4 Sanofi- Aventis DE 
5 Regie Nationale Des Usines Renault S.A. FR 5 SCA Hygiene products DE 
6 France Telecom FR 6 Aesculap & Company DE 
7 Astrazeneca AB SE 7 Karlstorz & Company DE 
8 
British 
Telecommunications 
Public Limited 
Company 
GB 8 Fresenius Medical Care DE 
9 Peugeot Citroen Automobiles S.A. FR 9 Novo Nordisk DK 
10 Infineon Technologies Ag DE 10 St. Jude Medical SE 
 Table 4.1: The top-10 most patenting active companies in the mechanics and medical device sector  
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The similarities between the two sectors traced back to the origins of the medical device 
sector and remains over time.  
For what concerns the composition of the applicants by age, we can see that the 
applicants of the medical device sector are relatively “young.” The 16% are less than 10 old, the 
37% are from 10 to 20 years old, the 43% are between 20 to 50 years old and the remaining 2% 
is older than 50 years. We see a very similar composition for what concerns the age of the 
applicants for mechanics. The 24% have less than 10 years, the 27% is between 10 and 20 years 
old, the 47% is between 20-50 years old, and the remaining 2% is older than 50 years. 
If we look at the distribution of the innovative actors of the two sectors by country 
across Europe (see Figure 4.1), we see that the top-three countries are Germany, Great Britain, 
and France, while the countries that are poorly innovative in one sector are poorly innovative 
also in the other. 
 
Figure 4.1: Applicants’ distribution by country across Europe 
 
Looking at the legal status, the applicants of the two sectors are assigned to five distinct 
categories: companies, government institutions, universities, hospitals and individuals. Overall, 
approximately 70% of the applicants are individuals followed by companies that represent about 
25%, and government institutions and universities represent the residual categories (see Figure 
4.2).  
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Figure 4.2: Applicants’ distribution by legal status  
 
Looking at the specialization of the innovative actors of the two sectors, we observe 
that the majority of applicants are fully specialized in their technology. In other words, they have 
100% of their patent portfolio composed only by patents of their own technology. The 
applicants with a mixed fifty-fifty composition of technologies in their patent portfolio follow in 
terms of importance (see Figure 4.3).  
 
Fig 4.3: Specialization of Mechanics applicants vs. Medical Device applicants 
 
 
While the sectors show a very similar innovative trend pre-1993, they have started to 
differ soon after.  For what concerns the evolution over time of the number of innovative actors 
we notice that the two sectors have a very similar trend until 1992. After that, mechanics had a 
huge boom, redoubling the amount of companies active in patenting while the medical device 
sector growth rate remains much smaller (see Figure 4.4).  
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Figure 4.4: Comparison between the number of applicants per year per medical devices and mechanics 
 
 
This trend is reflected in the patenting activity of the two sectors. Figure 4.5 shows that 
the two sectors have an identical trend before 1993 and then the medical devices sector deviated 
from mechanics.  
 
Fig 4.5: Patent trend of the medical device sector vs. the mechanics sector 
 
 The remarked deviations in the innovative trend of the medical device sector with 
respect to the trend followed by the mechanics sector after 1993 informed us about the effects 
of regulation that are analytically explored in the next section.     
4.5 Analysis 
Following the arguments delineated in the Introduction Section, we test two 
hypotheses: 
1. Regulation has a detrimental effect on the innovative content of an invention; 
2. Regulation stimulates the geographical diffusion of an invention. 
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In order to assess whether the introduction of Directive 93/42/EEC in 1993 has 
affected 1) innovative content and 2) the diffusion of an invention, we perform difference-in-
differences regressions that compare changes in the patenting behavior of medical device 
inventors with changes in the patenting behavior of mechanics inventors. In all our regressions 
the unit of analysis is a European invention patented in the medical device and mechanics sector 
during the observation period (1980-2012). 
In this section, we illustrate our dependent variables (sub-section 4.5.1), the 
econometric specifications used for the analyses (sub-section 4.5.2) and finally, the controls 
included in the econometric exercises (sub-section 4.5.3). 
4.5.1 Dependent variables for innovative content and the geographical diffusion of an 
invention 
Innovative content of an invention 
The innovative content of an invention can be evaluated along a continuum, between 
being incremental and being radical, with respect to the extant inventions.  
An incremental innovation does not bring any fundamental change in a treatment, nor 
does it bring about a crucial change in the product (Schumpeter, 1942). It requires a short 
development cycle and, due to the very low degree of change, its acceptance by the market and 
the regulation is almost a certainty. An example of this innovation could be an instrument to 
check for glycaemia, to be used by people suffering from diabetes.  Over the years, this device 
has become smaller, lighter, with a bigger memory to save historical data, and with a clearer 
screen. However, it has not significantly changed in terms of how patients use it. They still need 
to insert into the device a strip containing a drop of blood in order to know their blood sugar 
level.  
Radical innovations are generally defined as breakthroughs, compared to inventions 
that do not depart from the traditional path, but simply add a few elements of novelty to the 
existing ones (Anderson and Tushman, 1990; Ashford and Hall, 2011). However, there is no 
agreement in terms of a formal definition and measure of a radical innovation. Some scholars 
identify radical innovations by looking at technology trajectories. For instance, Dosi (1982) and 
Anderson and Tushman (1990) consider an innovation to be radical if it creates discontinuity in 
the technology trajectory, and if it destroys the existing equilibria. In line with these authors, 
Henderson (1993) develops the idea of a radical innovation as an instrument to enhance or 
destroy competencies. Other scholars examine the value of an invention and claim that it is 
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radical if consumers are willing to pay a higher price for it (Tirole, 1988). These approaches 
match the radical nature of an innovation with its impact on an industry, and on the market in 
terms of its ability to break with tradition in the field and to record commercial success. In the 
medical device sector, a radical innovation changes the therapy paradigm, with the consequence 
of providing a completely new product. Since this innovation is completely new, the reaction of 
the market is difficult to forecast. An example of this type of innovation is the balloon catheter. 
It is a small balloon used to open up a closed artery narrowed by plaque. Before this invention, 
artery occlusions were treated with a much more invasive operation. 
The debate on where radical innovations originate is still open. Some scholars state that 
radical innovations are the result of a recombination of existing knowledge (Cohen and 
Levinthal, 1990; Fleming, 2001; Von Wartburg et al., 2005). In this case, existing technologies are 
seen as blocks that can be combined to create something new.  Alternatively, the creation of 
radical innovations could be based on completely new knowledge (Poel, 2003). For instance, 
following this line of thought, Arthur (2009) and Christensen (2013) affirm that new 
technologies may appear without having any clear or major precedent. One mixed view is that of 
scholars such as Ahuja and Lampert (2001) and Boyd et al. (2011), who argue that a radical 
invention could use old technologies or emerging ones, or a combination of both.  
In our study, in order to evaluate the innovative content of an innovation, we refer to 
Fleming’s “component familiarity” index (2001), which proxies for the level of familiarity that 
inventors have with the components of their inventions. Our dependent variable, Familiarity, is 
based on the idea that each IPC code is a distinct knowledge component of an invention (Dosi, 
1982; Fleming and Sorenson, 2001; Strumsky and Lobo, 2015). Therefore, a radical invention is 
built on new combinations of IPC codes, whereas an incremental invention replicates the 
combinations of IPC codes used by extant inventions. To construct our Familiarity measure, we 
proceed in two steps. First, we list the combination of IPC codes to which the focal invention is 
assigned. Then, we look back in time to see whether this combination has already been assigned 
to other inventions. If this is the case, an indicator function assumes the value of 1, and 0 
otherwise. Then, we multiply the indicator function by an exponential function, where the 
exponent is the ratio between the priority application date of the two patents and a time constant 
of knowledge loss44. Finally, the components are summed. The Familiarity measure for the focal 
patent i is summarized by the following formula: 
                                                          
 
44 Following Fleming (2001), we assume that there is a yearly knowledge loss of 18%.  
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(Equation 4.1) 
When the focal invention has a unique IPC codes combination with respect to all 
previous inventions, the index is equal to 0, i.e., the invention is radical in nature because 
inventors have no familiarity at all with the specific code combination. The value of the index 
increases when the focal invention replicates existing IPC codes combinations. Therefore high 
values indicate that the invention is incremental in nature. 
The Familiarity measure is computed using a 4 IPC code digit level of precision, 
corresponding to the definition of a subclass (example A61F). In Appendix 4.2, we report an 
illustration of how to compute a single component of the sum reported in Equation 4.1.  
The geographical diffusion of an invention 
The geographical diffusion of an invention is the second aspect of the innovation 
dynamics that we analyze. We use the geographical protection of an invention as proxy for its 
geographical diffusion. 
Patents give to its owners the exclusive right to use and produce an invention; however, 
this right is limited in space. This spatial limitation is related to the specific country where the 
patent application has been filed. When an applicant decides to apply for a patent, she can 
choose to protect it in just a few countries, or she can choose to have protection in all of the 
countries covered by the European Patent Office (EPO) contracting states45. In the first case, the 
applicant follows the national procedure of the state where the applicant intends to protect her 
invention. In the second case, the applicant guarantees to the patent broader protection, i.e., the 
patent, once granted, provides protection in all of the contracting states, even if only a unique 
application has been filed. The national and EPO procedures are not mutually exclusive. A 
patent application could be filed first to a national patent office, and later, within twelve months, 
the applicant can ask for an extension at the EPO 46 (Archibugi, 1988; Gay et al. 2005). 
Our measure of diffusion, Geo Diffusion, is a variable that counts the number of national 
patent offices where a patent has been filed.  In the case of an EPO application, the number of 
                                                          
 
45 An applicant can also decide to go through USPTO or other patent offices external to Europe. However, this 
procedure is beyond the aim of this paper, since we are focusing our attention on Europe. 
46 See Euro-PCT guide, point 449 ff (January 2016). 
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patent offices where the protection of a patent has been extended is not available. In order to 
overcome this problem, we decided to count for 18 countries, corresponding to the number of 
members states in 1993. In constructing this variable, we have taken into account only patent 
offices in Europe because we are interested in studying the diffusion of an innovation within 
Europe. 
4.5.2 Econometric specifications  
The innovative content of an invention 
Figure 4.6 reports a graphical illustration of how the content of an invention, measured 
by our Familiarity measure, changed over time in Europe for the medical device sector and 
mechanics.  
 
Figure 4.6 – Comparison of the familiarity index between the Medical device sector and Mechanics. 
 
This graphical evidence shows that, the degree of innovative content of Mechanics 
patents remains quite constant over time. On the contrary, with the introduction of a strict 
regulation, medical devices inventors became risk adverse toward novelty.  
To formally evaluate whether the introduction of the EU regulation in 1993 had an 
impact on the Familiarity of subsequent inventions, we estimate an Ordinary Least Squares (OLS) 
model for the following equation 
Familiarityi=β0+β1Regulation+ β3MD  + β4 (Regulation*MD) +β2CInventioni +β3CApplicanti+εi 
(Equation 4.2) 
where MD is a dummy that equals 1 for inventions in the medical device sector and 
equals 0 for inventions in the mechanics sector. Regulation is a time-related dummy that takes a 
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value of 0 if the invention was filed before 1993, and a value of 1 in the following years (that is, 
after the introduction of Directive 93/42/EEC). The interaction term Regulation*MD marks 
observations from the medical device sector after the Directive introduction. After the 
introduction of the regulation, incremental innovations became more attractive for medical 
device inventors with respect to radical ones. For mechanical inventors the incentive to 
implement radical innovations remains the same. Thus, we expect the coefficient of the 
interaction term to have a positive sign.  
In addition to the absence/presence of a regulation at the European level, we expect 
the absence/presence of a national regulatory authority to affect the innovative content of an 
invention. To control for this aspect, we add National Office, a dummy that is equal to 1 if the 
invention was realized in a country where there was a National Agency for Heath Safety in the 
invention application year. Furthermore, we include two types of controls. The variables in 
CInventioni measure the characteristics of invention i, and those in CApplicantj measure the 
characteristics of the invention applicant/s. Finally, we add the country fixed effects to control 
for local characteristics of the country where the invention is realized and the cumulative number 
of patents to control for the innovative trend path. 
The geographical diffusion of an invention 
Figure 4.7 reports a graphical illustration of how an invention’s degree of diffusion changed over 
time in Europe in the two sectors. The figure shows that around 1993 medical device inventions 
diffuse more than mechanics inventions that remain stable and in certain years diffuse less.  
 
Figure 4.7 – Comparison of the geographical diffusion between the Medical device sector and Mechanics 
 
To formally evaluate whether the introduction of Directive 93/42/EEC impacts the 
Geo diffusion of a specific invention, we estimate a count regression model that accounts for the 
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fact that our dependent variable can only take positive integer values, i.e., the number of national 
patent offices where a patent has been filed. 
The conditional expectation of invention i’s number of national patent offices can then 
be expressed as follows: 
??= exp(β1Regulation+ β3MD  + β4 (Regulation*MD) +β2CInventioni +β3CApplicanti) 
(Equation 4.3) 
where the interaction Regulation*MD is expected to have a positive effect on Geo 
diffusion. In other words, inventions affected by the regulation are expected to diffuse more than 
the inventions in the control group since the standardization guaranteed by the regulation 
stimulates inventors to submit their patents to a greater number of patent offices. For invention 
and applicants’ characteristics, we used the same ones listed in the analysis of the technological 
content of an invention. The controls mentioned are described in the next sub-section. 
4.5.3 Controls included in the econometric exercises  
National Agency for Heath Safety 
Each EU state member has established, at different moments in time, a national 
authority that is responsible for the quality, safety and efficacy of medicine and health products. 
The majority of them have a specific section that monitors medical devices in the country. In our 
study, we construct a dummy variable, National Agency, which assumes a value of 1 if the 
invention is filed after the country has established its national agency47. Table 4.2 reports the list 
of EU National Agencies for Health Safety with their corresponding established year. 
Country Agency Established year 
Austria Austrian Agency for Health and Food Safety 2002 
Belgium Federal Agency for Medicine and Health Products 2007 
Denmark Danish Medicine Agency 2015 
Finland Finnish Medicine Agency 2009 
France National Agency for the Safety of Medicine and Health Products 2011 
Germany Federal Institute for Drugs and Medical Devices 1975 
Greece National Organization for Medicine 1983 
Ireland Health Product Regulatory Authority (HPRA) 1996 
Italy Italian Medicine Agency 2003 
                                                          
 
47 Each patent is assigned to the country corresponding to the first inventor address (see the “Data” section). 
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Country Agency Established year 
Luxembourg Ministry of Health 1980 
Netherland Medicine Evaluation Board 1995 
Portugal National Authority of Medicine and Health Products 1993 
Spain Spanish Agency for Medicine and Health Products 1999 
Sweden Medical Product Agency 1994 
United 
Kingdom 
Medicine and Healthcare Product Regulatory Agency 2003 
Table 4.2 – List of EU National Agencies for Health Safety with their corresponding established year. 
Invention characteristics (CInventioni) 
CInventioni is a vector of controls related to invention i. The included variables are 
standard controls considered in the patent literature. The patent documentation keeps track of 
“prior art.” Scholars have used the Forward citations count– citations to the focal patent received by 
later patents – and Backward citations count– citations to previous patents made by the focal patent- 
to measure the value and the technical content of an innovation, respectively.  
Harhoff et al. (1999) explain the logic behind the use of forward citations as a measure 
of a patent’s value. They show that the economic value is proportional to the amount of forward 
citations received. Many works rely on the belief that receiving a large amount of citations is a 
proxy for identifying a radical patent, due to the fact that radical inventions establish the 
technical basis for subsequent inventions (Trajtenberg, 1990; Dahlin and Behrens, 2005; 
Schoenmakers and Duysters, 2010). Katila’s work (2000) criticizes the positive correlation 
between forward citations and patent value. She proves that patents referred to as radical 
innovations are less cited than non-radical ones. This can be due to difficulties in understanding 
the new technology, the impossibility of embedding it directly into the existing process, or simply 
to a time lag in recognizing the innovative value of the invention. 
Backward citations map the knowledge upon which an invention relies (Jaffe, 1986; 
Reitzig, 2003; Rosenkopf and Nerkar, 2001). We interpret the variable Backward citations count as 
the amount of knowledge that has been necessary to realize the invention i. We argue that an 
invention that is more incremental needs less prior knowledge than a radical one.  A possible 
concern might be that the Backward citations count could be consider as a measure of how 
knowledge has been recombined (Fleming, 2001) and to evaluate if new elements have been 
introduced to the extant ones (Hargadon et al., 1997). However there is not common consensus 
in looking at backward citations as a proxy for the novel content of an invention (Ahuja and 
Lampert, 2001; Rosenkopf and Nerkar, 2001; Shane, 2001; Stuart and Podolny, 1995). Moreover 
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in our dataset the correlation between our measure of innovative content, Familiarity, and 
Backward citations count is very low (2%). This result reassures us in keeping Backward citations count 
as control in our estimated models.  
Additionally, we use the Backward citations average age in order to capture the time lag 
window, where the invention draws its technological references. The assumption is that 
inventors are more familiar with technology components that have been recently used (Fleming, 
2001). The Forward citations average age proxies for the time lag period that the invention requires 
to be absorbed and applied by others. Radical inventions might require more time to be 
understood (Katila, 2000). Finally, we introduce the Count of citations to non-patent literature. 
Previous studies have found that references to scientific literature denote greater closeness to a 
breakthrough than to an established technology, i.e., a great degree of novelty (Carpenter et al., 
1981). Additionally, in the case of a medical device, references to scientific literature are required 
so as to add clinical data support as proof of the invention’s reliability.  
Applicants’ characteristic (CApplicant j) 
CApplicant j is a vector of controls related to the applicants’ characteristics. Over the 
past century, the process of knowledge creation has fundamentally changed. Nowadays, 
collaborative models have mainly replaced the individualistic-based model of discovering 
activities (Wuchty et al., 2007). Previous studies have shown a positive impact of collaboration 
on the inventions’ impact (Jones et al., 2008). Consistent with these studies, we include the 
collaboration dimension as the number of applicants, Count of applicants. The Applicants’ Age is an 
indication of the average age of the applicants. Finally Applicants’ Specialization is an indication of 
the average technological specialization of the applicants. It is calculated as the average of the 
patent portfolio specialization in the focal sector (medical device or mechanics) of all the 
applicants involved in invention i. 
Other controls 
As an additional control, we include the number of cumulative active patents at time t-
1, Number of cumulative patents, as a proxy for the innovative trend. 
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Variable 
Mean Std. Dev. Min Max 
Familiarity index 374.83 729.20 0.00 7541.58 
Geographical diffusion 12.56 9.44 0.00 49.00 
Regulation 0.83 0.37 0.00 1.00 
MD 0.22 0.41 0.00 1.00 
National Agency 0.62 0.49 0.00 1.00 
Invention characteristics 
Backward citations count 8.58 10.49 0.00 339 
Forward citations count 11.41 51.93 0.00 3598.00 
Backward citations average age 9.95 7.90 0.00 108.00 
Forward citations average age 4.19 4.34 0.00 49.88 
Count of citation to non-patent 
literature 39.41 218.43 0.00 21060.00 
Applicant's characteristics 
Count of applicants 2.12 1.63 1.00 28 
Applicants’ Age 11.78 17.41 0 128 
Applicants’ Specialization 44.36 31.47 0.00 100 
Other controls 
Number of cumulated patents 160981.30 94311.92 3954.00 285173.00 
 Table 4.3 - Descriptive statistics48. 
Descriptive statistics are reported in Table 4.3.  
4.6 Results 
Innovative content of an invention  
The regression results from estimating equation 4.2 are presented in Tables 4.4 49.  
 
 
 
 
 
 
 
 
 
 
 
                                                          
 
48 Notes: Number of observations= 543,667 (unit of analysis: invention)  
49 For all the tables robust standard errors are in parentheses: *** p<0.01, ** p<0.05, * p<0.1. The unit of analysis is 
the invention i. 
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Variables 
I II 
Coeff. Std. Err Coeff. Std. Err 
Regulation -84.844*** (22.627) -84.767*** (22.977) 
MD 670.146*** (14.667) 664.681*** (16.038) 
Regulation*MD 678.331*** (55.140) 677.488*** (56.867) 
National Agency 20.025 (11.778) 
Invention characteristics 
Backward citations count -1.554*** (0.363) -1.533*** (0.364) 
Forward citations count -0.368*** (0.058) -0.357*** (0.064) 
Backward citations average age -4.597*** (0.638) -4.584*** (0.653) 
Forward citations average age -3.778*** (0.611) -3.548*** (0.792) 
Count of citations to non-patent 
literature 0.103*** (0.031) 0.103*** (0.032) 
Applicant's characteristics 
Count of applicants 5.573** (2.095) 6.191*** (2.035) 
Applicants’ Age -0.152 (0.446) -0.214 (0.418) 
Applicants’ Specialization -1.186** (0.437) -1.168** (0.432) 
Other controls 
Cumulative number of patents 0.001*** (0.000) 0.001*** (0.000) 
Constant 163.567*** (29.092) 154.065*** (28.047) 
Country FE YES 
Observations 543,667 543,667 
R-squared 0.424 0.424 
Table 4.4 - OLS estimation results for Familiarity. 
 
 
Table 4.4 reports the results of our econometric exercise. We consider two 
specifications. In column I, we consider only the effect of Directive 93/42/EEC; in column II, 
we add a control for the presence of a national authority, National Agency, which regulates the 
sector in the country where the invention was filed.    
In Table 4.4, as expected, the interaction term Regulation*MD has a positive effect on 
the Familiarity index, i.e., inventions filed after the introduction of Directive 93/42/EEC by 
medical device inventors are more incremental with respect to the ones filed by mechanical 
inventors. These findings prove that Directive 93/42/EEC was one of history’s great watersheds for the 
medical device sector. 
We would like to highlight some remarkable results regarding the other controls. The 
coefficient of Backward citation count is significant and negatively correlated with the level of 
familiarity of an invention. Thus, incremental innovations need less amount of previous 
knowledge in order to be developed with respect to radical innovations. The coefficient of 
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Forward citation count is significant and negatively correlated with the level of familiarity of an 
invention. This result is in line with the idea of the scholars arguing that radical innovations are 
associated with a higher value and are consequently cited more often than incremental 
innovations. The coefficient of the average age of backward citations, Backward citation average age, 
is negative correlated with invention familiarity level. Inventions with a greater level of novelty 
draw their technological references far back in time. It seems that in order to develop radical 
innovations, companies need to look further in time and maybe to forgotten technologies. The 
coefficient of the average age of forward citations, Forward citation average age, is negatively 
correlated with the invention familiarity level. Thus, inventions with a greater level of novelty are 
cited in the short run.   
Regarding applicants’ controls, the coefficient of the Count of applicants has a positive 
sign. This means that larger teams realize inventions with a greater level of familiarity. This result 
suggests the idea that the creation of radical innovation is more likely to happen within smaller 
teams. The coefficient Applicants’ Specialization is negatively correlated with the incremental level 
of the innovation. This result suggests that companies with a deep sectorial knowledge are more 
likely to realize radical inventions.  Similarly, the coefficient Applicants’ Age is negatively 
correlated with the invention familiarity level suggesting that younger firms are more willing to 
produce radical inventions.  
The coefficient of the number of references to non-patent literature, Count of citation to 
non-patent literature, is positively and significantly correlated with the invention familiarity level. 
This could be related to the nature of a medical device invention that requires the demonstration 
of clinical trials in order to be marketable.  Finally, also the coefficient Cumulative number of patents 
is positively correlated with the invention familiarity level, underlining a correlation between the 
trend of patenting and a higher probability for an innovation to be incremental. 
When we add the control for the presence of a national agency in the country, National 
Agency, the results remain stable across the specifications. Moreover, the coefficient of the 
dummy National Agency has no correlation with the innovative content of inventions. 
Geographical diffusion of an invention 
The regression results from estimating equation 4.3 are presented in Tables 4.5.  
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Variables 
I II 
Coeff. 
Std. 
Err Coeff. 
Std. 
Err 
Regulation -0.044*** (0.005) -0.042*** (0.005) 
MD 0.032*** (0.007) 0.056*** (0.006) 
Regulation*MD 0.040*** (0.009) 0.067*** (0.009) 
National Agency -0.183*** (0.004) 
Invention characteristics 
Backward citations count 0.011*** (0.000) 0.011*** (0.000) 
Forward citations count 0.001*** (0.000) 0.001*** (0.000) 
Backward citations average age 0.005*** (0.000) 0.005*** (0.000) 
Forward citations average age 0.009*** (0.002) 0.009*** (0.002) 
Count of citations to non-
patent literature -0.000*** (0.000) -0.000*** (0.000) 
Applicant's characteristics 
Count of applicants 0.065*** (0.001) 0.063*** (0.001) 
Applicants’ Age 0.003*** (0.000) 0.003*** (0.000) 
Applicants’ Specialization -0.003*** (0.000) -0.003*** (0.000) 
Other controls 
Cumulative number of patents -0.000*** (0.000) 0.000*** (0.000) 
Constant 2.434*** (0.016) 2.452*** (0.017) 
Country FE YES YES 
Observations 543,667 543,667 
Pseudo R-squared 0.086   0.089   
Table 4.5 – Poisson Estimations for number of patent offices where an invention i is filed. 
 
 
To analyze how Directive 93/42/EEC affects the diffusion of an invention, we 
perform an econometric exercise that replicates the same specifications used in Tables 4.4. We 
present in column I the baseline model, and in column II, we add the National Agency variable. 
Our results show that after the introduction of Directive 93/42/EEC, medical device 
inventions are filed to a greater number of patent offices with respect to mechanical inventions. 
In other words, a medical device applicant is stimulated to invest in broader geographical 
protection than a mechanical one, since, having fulfilled the standard of a European regulation, 
she is more confident that her invention will be accepted beyond her national borders.  
Regarding the controls, the coefficient of Backward citation count is significant and 
positively correlated with the diffusion of an invention. We have seen in the previous paragraph 
that radical innovations are characterized by referencing a higher number of citations. Thus, it 
seems that radical innovations diffuse broader than incremental innovations. The coefficient of 
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Forward citation count is significant and positively correlated with the diffusion of an invention. As 
before, we have seen that radical inventions are cited more than incremental. Thus, we can argue 
that radical innovations diffuse more than incremental. The coefficient of the average age of 
backward citations, Backward citation average age, is positively correlated with diffusion. Inventions 
that, on average, cite older prior art diffuse broadly. This result supports the results presented in 
discussing the relationship between age of the prior art cited and invention familiarity level. The 
coefficient of the average age of forward citations, Forward citation average age, is positively 
correlated with the diffusion of an invention. Thus, an invention that, on average, receives 
citations several years after its publication diffuses broadly.  
Regarding applicants’ controls, the coefficient of the Count of applicants has a positive 
sign. This means that the invention developed by larger teams diffuse largely. The coefficient 
Applicants’ Specialization is negatively correlated with the diffusion of the innovation. This result 
shows that inventions developed by companies with a deep sectorial knowledge are less capable 
to diffuse their inventions.  The coefficient Applicants’ Age is positively correlated with diffusion 
suggesting that the innovations developed by older firms circulate more than the ones developed 
by younger companies. 
The coefficient of the number of references to non-patent literature, Count of citation to 
non-patent literature, is negatively and significantly correlated with diffusion. This result seems to 
suggest that inventions that refer less to non-patent literature diffuse more. Finally, the 
coefficient Cumulative number of patents is positively correlated with the invention diffusion, 
underlining a correlation between the trend of patenting and a higher probability of circulation. 
In the specification that adds the dummy National Agency the results are consistent. The 
coefficient of National Agency has a negative correlation with the diffusion rate of inventions. This 
suggests that those inventions in countries where there is an agency which control the innovative 
output diffuse less than the ones where there is no control. 
4.7 Conclusions 
We evaluate the impact of the introduction of a regulation on (1) the technological 
content; and (2) the geographical diffusion of an innovation. We create a novel dataset of 
543,667 inventions introduced in the European medical device and mechanical sectors in the 
period 1980-2012. We find that innovative content for invention in MedTech decreased 
significantly after 1993 with respect to inventions in mechanics. Moreover, after 1993, MedTech 
applicants tended to file their inventions more broadly, assuring an extension of the geographical 
protection to their invention.  
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Unique to our study is the fact that, in considering regulation effects on innovation 
activities, we look at the technical content of each invention. Specifically, we consider the 
technologies embodied in an invention. We find that, after the regulation change, MedTech 
innovators tend to replicate extant technology combinations instead of introducing new ones. 
This result indicates that MedTech innovators became more risk adverse toward novelty. At the 
same time, a stringent regulation at the European level imposes the standardization of products 
to all European countries. If patent applicants can rely on uniform rules that their products have 
to satisfy, they are incentivized to file their applications broadly. In other words, moving from a 
defragmented combination of different rules to a uniform set of rules with broad coverage, leads 
MedTech applicants to extend their targeted markets, while for Mechanics ones things remain 
unchanged. 
The results have direct implications for the literature on the impact of social regulations 
on innovation. This literature claims that public intervention favors innovation activities (Porter 
et al., 1995), but the extant empirical evidence provides contradictory results (Blind, 2012). While 
previous studies measure innovative dynamics as patent applications or firm performance, our 
study explores invention characteristics in terms of content and geographical extension 
protection. Going beyond the simple patent counts and firm balance sheet accounts allows us to 
investigate how regulation affects the nature of an innovation. Specifically, we find that 
regulation discourages radical innovations. Products based on existing technologies are easier to 
be accepted as safe than products that break with the past. If a regulation appears to downsize 
the invention innovative content, on the other side, it seems to guarantee a wide market to an 
invention for its commercialization. The existence of a common set of rules in a large economic 
space such as that of the EU assures standardization and limits the negative effects of a 
patchwork of national norms.    
Although our analysis provides interesting results, it is not exempt from limitations. 
First, the use of patent data includes some limitations as a no one-to-one correspondence with a 
device. Moreover not all the inventions are patented. We try to overcome one of the limitations 
in the use of patent data, the overestimation of the count of patent data. For this reason we use 
patent families that group in one single observation all the applications that identify a unique 
innovation. Second, an alternative explanation could apply for the decline of the innovative 
activities observed. Innovative activities might decline because inventors became more reluctant 
to exploit opportunities at the technological frontier, even in the absence of a specific regulation 
because they do not want to incur the risk of harming patients by experimenting with unknown 
techniques. However, we cannot ignore than in the last decade, a large number of original 
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medical devices have been introduced. The bio-artificial liver that was listed by the Times as one 
of the most important inventions of 2001 is just an example. The bionic contact lens, mind-
reading, and eye-wither devices provide other examples of the most innovative efforts in the 
medical device sector. For this reason, we refrain to formulate any consideration regarding the 
value of individual innovation. 
Our results have important implications for policymakers. When policymakers 
introduce a strict regulation, they think about the health and security for the final users. 
However, they should also consider the “side-effects” for the economy. A more stringent 
regulation might discourage inventors from introducing new risky solutions. In response to this, 
we believe that, in planning their interventions, regulators should listen to the opinions of small 
companies and medical device experts in order to introduce norms that guarantee patient safety, 
but at the same time, meet the needs of the sectorial operators. Of course, we do not want to 
make general statements, and we are aware that our study is limited to a specific sector. 
 
Appendixes 
Appendix 4.1 
Applicants’ name harmonization 
In order to retrieve applicants’ names, we relied on the PATSTAT Person Augmented 
Table (EEE-PPAT). Specifically, we used the PATSTAT Table TLS206_PERSON & 
TLS906_PERSON (December 2014), which includes patentees’ harmonized names and classifies 
assignees by organizational type.   
This table is the result of a project launched in 2006 by EUROSTAT in collaboration 
with EPO, ECOOM (KU Leuven) and Sogeti. In this appendix, we provide an overview of the 
method they applied for name harmonization and organizational type assignment in order to 
clarify the data- cleaning procedures behind our data sources. Interested readers can find a 
detailed explanation of the method leading to the table creation in Du Plessis et al. (2009), 
Magerman et al. (2009), and Peeters et al. (2009).  
The name harmonization and patent application assignment is a three-step process. 
First, applicants’ row names undergo a pre-cleaning standardization procedure, where spaces and 
all non-alphabetical characters are deleted, and characters and punctuation are standardized. 
Also, the applicants’ legal form is treated so as to appear normalized. Second, strings are 
compared to find word similarities, based on spelling variations. Finally, cleaned names are 
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matched with the original ones and grouped, and patent applications are reassigned to the 
harmonized names.  
The applicants’ organizational type classification considers the following categories: 
private business enterprises, universities/higher education institutions, governmental agencies 
and individuals. The first step of the algorithm regards the automatic research into the name 
string of some “clues” that help in identifying to which sector a name belongs, such as legal 
forms for companies or governmental agencies, or educational status for individuals, i.e., Doc., 
Eng.…  Due to the difficulties in connecting a “clue” to a unique sector, an additional validation 
step is included. This leads to the creation of a set of rules specific for each case and raises the 
quality of the result. The final quality level of the final dataset is 99%.  This means that 99% of 
the records have a sector assigned, and vice versa; 99% of the records are assigned to just one 
sector. 
Appendix 4.2 
 
Figure 4.8: Illustration of how to compute a single component of the sum supported in equation 4.1. 
Patent i uses the same IPC code combinations of patent k that was submitted 3 years 
before. The Familiarity index for patent i above is: 
????????????  = ? ? ?
?????????
? ? ??? 
IPC code combination (4-digits) 
k=A61B Application year k=2005 Application year i=2008 
IPC code combination (4-digits) 
i=A61B 
PATENT k 
PATENT i 
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Figure 4.9: Illustration of how to compute a single component of the sum supported in equation 4.1. 
 
Patent i does not use the same IPC code combination of patent k that was submitted 2 
years before. The Familiarity index for patent i above is: 
????????????  = ? ? ?
?????????
? ? ? 
 
Appendix 4.3 
In this appendix we report the results of an econometric exercise to test the robustness 
of the results reported in the main text. The analysis reported exploits a variation in the 
legislative status of each European country. We compute differences-in-differences estimates of 
the effects of the Directive for countries with a national agency and countries without a national 
agency. In order to perform this exercise, we add to equation 4.2 and 4.3 the interaction between 
the dummy Regulation and the dummy National Agency, Regulation*National Agency. This interaction 
term takes value 1 if an invention has been developed after 1993 in a country with a National 
Agency. The idea behind this specification is that the Regulation became effective only if 
combined with the presence of a National Agency that monitors the application of the 
Regulation. Having introduced the presence of a national agency as source of variability among 
country, we can apply differences-in-differences where we limit our empirical setting to the 
inventions in the medical device sector (117,993 observations).  
Table 4.6 shows that the first hypothesis, Regulation has a detrimental effect on the 
innovative content of an invention, is confirmed. Regulation has a positive effect on the Familiarity 
index, showing that invention after 1993 are incremental and not radical. The coefficient of 
the interaction term Regulation*National Agency does not have any effect on the innovative 
content. The results on the controls remain similar to the one presented in the main text with 
PATENT k 
PATENT i 
Application year k=2005 Application year i=2007 IPC code combination (4-digits) 
k=A61B 
IPC code combination (4-digits) 
i=A61B & A61F 
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the exception for two coefficient, Forward citation average age and Count of applicants. Forward 
citation average age is now negatively correlated with invention familiarity, whereas Count of 
applicants has now a negative sign. This could be interpreted as the fact that larger teams 
realize inventions with a greater level of novelty.  
The second hypothesis, Regulation stimulates the geographical diffusion of an invention, is 
confirmed. The coefficient Regulation*National Agency has a positive effect on the diffusion of 
the innovations. It seems that only countries with an active national agency are stimulated to 
diffuse more their inventions. The results on the controls remain similar to the one presented 
in the main text with the exception for two coefficient, Applicants’ Specialization and Count of 
applicants. 
Applicants’ Specialization is now positively correlated with invention diffusion and 
Count of applicants has now a negative sign. This means that smaller teams realize inventions 
with a greater potential of diffusion.  
The limitation of the use of this setting, compared with the one presented in the main 
text, is the impossibility to disentangle the effect of the Directive 93/42/EEC and the one 
related to the creation of the common market.  
Variables 
OLS Model Poisson Model 
DV Familiarity DV Geo Diffusion 
Coeff. Std. Err Coeff. Std. Err 
Regulation 157.680** (55.403) -0.026*** (0.008) 
National Agency -24.253 (29.689) -0.288*** (0.011) 
Regulation*National Agency 61.822 (47.037) 0.215*** (0.011) 
Invention characteristics 
Backward citations count -2.447** (0.883) 0.007*** (0.000) 
Forward citations count -0.159*** (0.042) 0.001*** (0.000) 
Backward citations average age -12.444*** (1.552) 0.010*** (0.000) 
Forward citations average age 6.732*** (1.191) 0.045*** (0.001) 
Count of citations to non-patent literature 0.673** (0.299) -0.002*** (0.000) 
Applicant's characteristics 
Count of applicants -43.783** (16.114) -0.072*** (0.006) 
Applicants’ Age -1.167* (0.611) 0.011*** (0.000) 
Applicants’ Specialization -3.807*** (0.689) 0.004*** (0.000) 
Other controls 
Cumulative number of patents 0.010*** (0.001) 0.000*** (0.000) 
Constant 864.738*** (42.556) 1.867*** (0.018) 
Country FE YES YES 
Observations 117,993 117,993 
R-squared 0.106 0.19 
Table 4.6 – OLS and Poisson Estimations including the interaction term Regulation*National Agency. 
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Chapter 5: Conclusions 
The medical device sector is nowadays an industry of tremendous success. By any 
measure, whether it be the number of firms, employment, number of global innovators, or 
export performance, this industry stands in a very high position. The sector presents itself as a 
very innovative business, characterized by a high density of innovators and a high degree of 
originality, thanks to its strong interaction with other fields, despite strict control on new 
products imposed by the regulatory framework. 
Since the beginning of its existence in the 1960s, the medical device sector has in its 
collaborative nature the driving force of its growth. As a matter of fact, everything began as a 
result of a joint effort of six Swiss surgeons who aimed to create an organization that could teach 
new techniques for orthopedic surgery. Very soon thereafter, this organization expanded and 
became an association that involved not only doctors, but also companies and medical schools. 
The companies who joined the association were not specialized in medical equipment; however, 
they were specialized in precision mechanics. Their technical competencies were central to 
helping doctors develop new devices. The creation of new tools soon became an interesting 
business opportunity. Suddenly other mechanical companies wished to take advantage of the 
new market and started to collaborate with surgeons. The problem was that at that time, there 
was no regulation to control the quality or safety of a device. Thus, in order to earn more money, 
companies used scarce materials, different from the ones agreed upon by doctors, causing 
serious illness in the patients using such devices. The need for control was so urgent that the AO 
surgeons established an internal quality check so as to assure high-quality tools.   
This thesis proposes three studies, providing novel empirical evidence related to the 
three main characteristics of the medical device sector: the network, knowledge spillovers and 
regulation, at the present.  
The second chapter of this thesis aims to understand the importance of the 
collaborative network of inventors for regional innovation. Previous literature has offered 
heterogeneous answers to the question: What is the best network structure to adopt in order to 
enhance innovative activities? Some scholars suggest the importance of proximity and co-
location of innovators in order to boost innovation. Others worry that a closed cluster could 
limit creativity and cause the circulation of redundant knowledge. In my first work, I analyze 
what the network structure that enhances regional innovative activity in the medical device 
sector. The results show that the ideal network structure is composed of intense internal 
connections between MedTech inventors, supported by external linkages. The results become 
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even stronger when well-connected MedTech inventors are linked with inventors specialized in 
other technologies. These findings highlight the importance of the combined effect of “home” 
connections, together with external linkages. The capacity of a region to benefit from external 
knowledge is determined by its internal connectivity. 
The third chapter extends the analysis concerning the importance of the knowledge 
exchanges between MedTech and other sectors. All scholars agree on the crucial role played by 
knoweldge spillovers for economic growth. For this reason, a hot topic in the literature regards 
the definition of a measure capable of tracking knowledge flows. The most frequently used 
measures are three: technological matrices, the Yale matrix, and patent backward citations. The 
dabate related to the degree of precision at which these measures actually estimate knowledge 
spillovers, especially when they occur across sectors, is still open. My study proposes a new 
definition of the measure of backward citations. In the analysis, I show how technologies are 
different in terms of the speed at which other sectors are capable of understanding, absorbing 
and using them. My hypothesis is that the existence of different adoption speeds should have an 
impact on the number of citations received by each technology from other sectors.  When I 
compare the classical measure of backward citations with my new results, I show: i) the 
technologies that were heavily cited before are still the most important, meaning that the new 
measure does not change the basic idea of the classical measure; ii) the technologies that were 
neglected before, but with a high adoption speed, start to appear as relevant. The aim of this 
study is therefore to carefully interpret the measure of backward citations when applied across 
sectors. 
In the fourth chapter, I analyze the effect of introducing the European regulation on 
medical devices in 1993 on the innovative performance of the sector. In recent years, strict social 
regulations have been introduced with the intent of guaranteeing consumers’ safety and health. 
The literature is mixed regarding the effects of regulation on innovation. Some scholars perceive 
the regulation as a limitation of natural technological evolution. Others see the regulation as an 
incentive for innovation. In order to study the effect of medical device regulation on the 
innovation of the sector, I create a novel dataset of European patents. The results show that the 
regulation has a negative effect on the radical nature of inventions. New medical device patents 
are built on more familiar component combinations in order to increase the odds of being 
accepted. At the same time, the regulation has the positive effect of opening the market and 
increasing the diffusion of the innovations. The existence of a common set of rules in a large 
economic space such as that of the EU assures standardization and limits the negative effects of 
a patchwork of national norms.   
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